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1. Asthma 
Asthma is defined as a heterogeneous chronic airway disease, characterized by chronic airway 
inflammation, variable remodeling, reversible airway obstruction and non-specific airway hyper 
reactivity (AHR) 1,2. The respiratory symptoms include wheezing, shortness of breath, chest tightness 
and cough 2. Often, these symptoms are accompanied by co-morbidities such as multi-organ allergies 
like allergic rhinitis, conjunctivitis, atopic dermatitis and food allergy. Furthermore it can be 
accompanied by non-allergic disorders such as obesity, gastro-oesophageal reflux and psychiatric 
conditions 2.  
Worldwide, more than 300 million people are affected by asthma, making it one of the most common 
chronic diseases. Although the disease is recognized worldwide, the prevalence of asthma depends on 
geographic location. In developed western countries the prevalence of asthma is estimated at 10% of 
the total populations, while in low-income and rural countries it tends to be less than 1% 2.  
1.1 Influence of genetic and environmental factors 
The origin and clinical phenotype of asthma are driven by genetic and environmental factors making 
asthma a heterogeneous disease. People can be genetically predisposed to develop allergic reactions 
to substances that do not generally elicit immune responses. Genome-wide association studies (GWAS) 
revealed genes susceptible for asthma. Most of these genes are related to the epithelium and innate 
immune pathways including ARMDL3, IL-33 and SMAD3. Less commonly, genes are found associated 
with atopy and serum IgE such as HLA-DQ locus, FCER1A, STAT6 and IL-13 3–5.  
Environmental risk factors have a prominent role in the development and exacerbations of asthma. They 
also modulate the expression of asthma susceptibility genes, making asthma a dynamic disease 6. 
Children sensitized to environmental allergens are more likely to experience persistent asthma later in 
life. During childhood, viral infections such as rhinovirus and respiratory syncytial virus (RSV) are 
associated with the development of asthma and are the most common cause of asthma exacerbations. 
Indoor and outdoor air pollution are important contributing factors to the development and 
exacerbation of asthma 2,7. Exposure to tobacco smoke boosts the Th2 type response and worsens 
existing asthma, probably through an increase of neutrophilic inflammation and oxidative stress 8. 
Occupational exposures can initiate asthma or aggravate existing asthma 8. Furthermore, obesity during 
childhood is strongly associated with the incidence and severity of asthma. Maternal obesity and high 
gestational weight gain are associated with an increased risk of childhood asthma, especially in non-
asthmatic mothers 2,9. Symptoms of asthma can also be experienced after exercise, named exercise-
induced asthma (EIA). Aspirin, an anti-inflammatory drug, is also an important trigger inducing asthma 
in some subjects, named aspirin-exacerbated asthma 10. In addition, according to the hygiene 
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hypothesis, increasing use of antibiotics, improved hygiene, and urbanization result in a decreased 
exposure to infections and environmental microorganisms during childhood. This results in a less Th1 
directed response to infections early in life, leading to a persistent imbalanced Th2 response and 
consequently asthma 6. 
1.2 Phenotypes and endotypes of asthma 
For years, asthma has been considered as a single disease. Recently, studies have focused on its 
heterogeneity as it is presented with diverse symptom profiles and variable responses to medications 
11. As already mentioned, the origin and severity of asthma are driven by genetic and environmental 
factors. All these factors result in different clinical outcomes also called phenotypes of asthma 12,13. A 
phenotype is defined as “observable properties of an organism that are produced by the interactions of 
the genotype and the environment” 13,14. Nowadays, it is recognized that asthma consists of multiple 
phenotypes. Phenotypes are described based on clinical characteristics such as the age of onset, severity 
(based on lung function, symptoms and exacerbations), inflammatory characteristics (predominantly 
eosinophilic, predominantly neutrophilic, paucigranulocytic, or mixed granulocytic), and response to 
standard and new therapies. Phenotypes can also be distinguished by differences in immunological 
mechanisms (Th1 or Th2 cell mediated response), biomarkers (blood/sputum levels of eosinophils, 
exhaled nitric oxide (FeNO), serum periostin and immunoglobulins) and imaging (Computed 
Tomography) 11,13–16. Additionally, phenotypes may be defined based on the causal agent or the trigger 
for worsening of symptoms such as occupational exposure, air pollution, cigarette smoke, diesel exhaust 
particles, aspirin, obesity, or exercise 13,14,17,18. Thus, Sally Wenzel grouped asthma phenotypes based on 
the distinction between Th2-high asthma and non-Th2 asthma (fig 1.1) 14. Nevertheless, substantial 
overlap exists among the different phenotypes 13. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.1: Different asthma phenotypes suggested by Sally Wenzel14. The intensity of the colors represents the severity of the specific phenotype. The relative size of the subcircles represents the relative proportions of affected individuals. 
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To clarify and further distinguish different phenotypes, research has focused on the molecular pathways 
involved in the asthmatic response, thus leading to the notion of endotypes. An ‘endotype’ is defined 
as “a specific biological pathway which can explain the observable properties of a phenotype” 14. Until 
now, there is no universal system to define asthma phenotypes, this results in researcher dependent 
categorizing of asthma patients 14.  
2. Pathogenesis of allergic asthma 
Traditionally, two forms of asthma have been distinguished in clinical practice: allergic and non-allergic 
asthma 14,16. Most children and roughly 50% of adults have allergic asthma. These people are atopic 
(they have a genetic predisposition to develop immunoglobulin E (IgE)), have identifiable allergic triggers 
(serum IgE antibodies and/or a positive skin-prick test), other allergic diseases (such as rhinitis or 
eczema), or a family history of allergic disease 14,16. This phenotype of asthma is characterized by 
humoral and T helper 2 cell (Th2) immune responses, resulting in infiltration of eosinophils, formation 
of allergen specific IgE antibodies and the release of Th2 cytokines.  
Non-allergic asthma often develops later in life (after 40 years age) and often has a more severe clinical 
course 19. This phenotype shows negative skin tests and has no evidence for specific IgE antibodies 
directed against common allergens, and has no clinical or family history of allergy 20. 
2.1  Immune mechanisms 
The pathogenesis of allergic asthma is the result of a complex interplay between innate and adaptive 
immunity. It comprise two phases, the induction (sensitization) phase and the elicitation (asthmatic) 
phase. The latter phase includes both early (EAR) and late (LAR) asthmatic reactions 21.  
2.1.1 Close interplay between epithelial barrier and dendritic cells  
Inhaled allergens, which passed the filtering of the upper airways, and escaped the mucociliary 
clearance, encounter the first line defense of the airways, namely the airway epithelial cells. Asthmatic 
epithelium has incomplete formation of tight junctions, which results in a defective barrier function. 
This can be the result of defective genes associated with the formation of the epithelium, but also 
proteolytic allergens (such as house dust mite, cockroach, animal and fungal) and environmental stimuli 
such as respiratory viruses and air pollutants (such as ozone, tobacco smoke and diesel particles). As a 
consequence, inhaled allergens can penetrate more easily into the airway tissue 22. 
When exposed to allergens, epithelial cells express many pattern recognition receptors (PRRs), such as 
toll like receptors (TLR), to rapidly detect and respond to pathogen-associated molecular patterns 
(PAMPs) (present on microbes) to damage-associated molecular patterns (DAMPs) (released upon 
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tissue damage, cell death or cellular stress). Upon activation of PRR, epithelial cells release specific 
cytokines (thymic stromal lymphopoietin (TSLP), granulocyte-macrophage colony-stimulating factor 
(GM-CSF), IL-25 and IL-33), chemokines (chemokine ligand (CCL)2, CCL5, CCL20, CCL27, CCL19) and 
danger signals such as uric acid and ATP, that direct monocytes and immature dendritic cells (DC) from 
the bone marrow towards the epithelium of the lung (fig 1.2) 5,23–25. Furthermore, IL-33, IL-25 and TSLP 
lead to an accumulation of type 2 innate lymphoid cells (ILC2) by acting on their receptors ST2, IL-17RB, 
and TSLPR respectively 26,27.  
Figure 1.2: Mechanisms of allergic asthma, according to Pelaia et al.30. Abbreviations: CXCL1, chemokine CXC motif ligand 1; IFNγ, interferon-γ; IL, Interleukin; MMP, matrix metalloproteinase; ROS, reactive oxygen species; TNFα, tumour necrosis factor-α; TSLP, thymic stromal lymphopoietin, TGFβ, transforming growth factor-β; Treg, regulatory T cells, TH0, naive T helper cells. 
Once arrived into the lung, DC extend their dendrites through the epithelial barrier to recognize and 
sample inhaled antigens from the airway lumen via PRR (such as TLR and NOD-like receptors) 22. During 
antigen sampling, DC preserve the integrity of the epithelial barrier by forming tight junctions with the 
adjacent epithelial cells 28. Upon signals secreted by the airway epithelial cells (IL-33, IL-25 and TSLP) DC 
become mature, activated and programmed to induce a specific T helper cell response 22. After being 
internalized, the allergen is processed into small peptides and presented via major histocompability 
complex (MHC) I and MHC II on the cell surface 24. Within a few hours of contact with the allergen, DC 
migrate towards the T cell area of the regional lymph node via a chemokine receptor (CCR)7 dependent 
manner in response to CCL7 5,29. The migration to the lymph nodes takes 12 hours and is accompanied 
by the expression of adhesion molecules and co-stimulatory molecules for naive T cells 24,29. At the T cell 
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area of the LN, programmed DC present epitopes of the processed allergen to naive T lymphocytes via 
MHCII/MHCI complexes, resulting in the induction of specific T helper cells 5,16,22.  
2.1.2 Different subsets and tasks of dendritic cells in mice  
Lung 
Originally, lung DC in mouse were described as a single population with a high degree of expression of 
CD11c and MHCII. To date, different DC subsets are described in the lung, each characterized by the 
expression of several cell-surface markers. The conventional dendritic cells (cDC) are characterized by a 
high expression of CD11c and are further divided into CD11b+ and CD103+ cDC. The monocyte-derived 
dendritic cells (moDC) are recognized by a high CD64+ expression and the plasmacytoid dendritic cells 
(pDC) are characterized by a high siglec-H expression (table 1.1) 24.  
Each of these DC subsets is geared to induce particular T cell responses. Nevertheless, this induction 
into a specific T cell seems to be context dependent 31.  
 CD103+ cDC are located between the epithelial cells of the conducting airways. They express the E-
cadherin-binding integrin CD103 and langerin and have the capacity, through the formation of tight 
junctions with bronchial epithelial cells, to extend dendrites into the airway lumen (fig 1.3) 22,32. 
They are specialized in cross-presentation of exogenous antigens to CD8+ T cells, and have the 
capacity to induce tolerance 31,33,34. Ex vivo they have also been shown to induce a type 1 T helper 
(Th1) or a Th2 cell response 31,34.  
 CD11b+ cDC are located in the lamina propria of the conducting airways (fig 1.3). In a HDM mouse 
model, they have been shown to be prone to induce a Th2 mediated immunity, while in a fungal 
model a Th17 mediated immunity was reported 31,33.  
                Fig 1.3: Lung dendritic cells subset from Lambrecht and Hammad 22.    
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 pDC are found in the alveolar septa and in the large conducting airways. Yet, their specific 
anatomical location is largely unknown 22. pDC are recognized by the expression of siglec-H and are 
important for controlling overt airway inflammation through induction of regulatory T (Treg) cells 
33,35.  
 Under inflammatory conditions, monocytes migrate to the local tissue and differentiate into moDC 
33. This subset is distinguishable from CD11b+ cDC by using the markers CD64 and/or MAR1 33,34. 
moDC have been shown to be sufficient to induce a Th2 immunity. The main function of moDC is 
situated in the lung as they poorly migrate to the draining lymph nodes due to the lack of CCR7 
expression. In the lung, they produce chemokines attracting Th2 cells to the lung 22,33,34.  
 Skin 
In the skin, CD11b+ cDC, are the most abundant type of DC. They have been shown to induce Tregs cells 
upon migration to the draining lymph nodes. Additionally, they are able to prime Th2 differentiation 
following skin sensitization in response to TSLP. Dermal (CD11b-)XCR1+cDC highly express CD207, and 
comprise both CD103+ and CD103- cells. XCR1+CD103+ dermal cDC have been shown to induce Th1 cells 
during infections. Monocyte derived dendritic cells are CD64low/+ and have a poor migratory capacity. 
Langerhans cells (LC) in the skin interact, via their expression of E-cadherin, closely with the surrounding 
keratinocytes. LC encompass both CD207 and CD11b expressing cells. Depending on the nature of the 
sensed threat, they can become immunogenic or tolerogenic. They have been shown to be responsible 
for the induction of naive T cells into Th17 or Treg cells. pDC are only identified in inflamed skin where 
they promote wound repair and mediate the systemic pro-inflammatory response (table 1.1) 36. 
Table 1.1: Subsets of lung and skin dendritic cells 31,33,36,37.  DC subsets Surface molecule expression 
Lung CD11b+cDC  
CD103+cDC 
CD45+CD11c+MHCII+CD11b+CD103- 
CD45+CD11c+MHCII+CD11b-CD103+ 
 moDC  CD45+CD11c+MHCII+CD11b+CD64+ 
pDC  CD45+CD11cdimMHCII+Siglec-H+ 
Skin CD11b+cDC CD45+CD11c+MHCII+CD64-XCR1-CD207-CD11b+ 
CD103+XCR1+cDC 
CD103-XCR1+cDC 
DNcDC 
CD45+CD11c+MHCII+CD64-XCR1+CD207+CD11b-CD103+ 
CD45+CD11c+MHCII+CD64-XCR1+CD207+CD11b-CD103- 
CD45+CD11c+MHCII+CD64-XCR1-CD207-CD11blow 
moDC CD45+CD11c+MHCII+CD64+ 
 LC CD45+CD11c+MHCII+CD64-XCR1-CD207+CD11b+ 
 
 Chapter 1 
9  
2.1.3 Induction of an immune response  
Once arrived at the T cell area of the local lymph node, DC will polarize naive T cells towards specific T 
helper cells. After being programmed by the epithelial cell derived cytokines IL-33, IL-25 and TSLP 
combined with IL-4 (derived from basophils, eosinophils, natural killer T cells and T cells), DC polarize 
naive T cells towards Th2 cells 22,38. Th2 cells may be important in mild to moderate asthma and are 
important producers of IL-4, IL-5, IL-6, IL-9, IL-13 and GM-CSF (fig 1.2) 38. Additionally, innate lymphoid 
type 2 cells (ILC2) are also important sources of IL-5, IL-9 and IL-13 and, to a lesser extent IL-4. IL-5 is 
responsible for recruitment and activation of eosinophils to the lung. IL-9 attracts mast cells and triggers 
their differentiation, while IL-13 is involved in different aspects of airway inflammation, remodeling and 
AHR. IL-4 and IL-13 act on B-lymphocytes by driving immunoglobulin class switching towards the 
production of antigen-specific IgE (fig 1.2) 39.  
After the production of antigen-specific IgE, they become systemically distributed where they bind to 
high affinity receptors (FcεRI) expressed on the surfaces of mast cells. Re-exposure to the same allergen 
leads to binding of the allergen on IgE antibodies that are attached to the mast cell FcεRI receptors. This 
causes coss-linking of the FcεRI receptors, which activate mast cells to release preformed mediators 
(histamine, serotonin, proteases and proteoglycans), newly synthesized lipid mediators (prostaglandins 
and leukotrienes and platelet-activating factor (PAF)) and increase the synthesis of many cytokines, 
chemokines and growth factors (TNF-α, IL-4, IL-5, IL-3, GM-CSF, TGF-β, vascular endothelial growth 
factor (VEGF)) (fig 1.2). The rapidly secreted preformed mediators contribute to the symptoms 
associated with the EAR that develop within 20-30 minutes. These symptoms include vasodilation, 
increased vascular permeability, increased mucus production and contraction of the bronchial smooth 
muscle. Meanwhile, mast cells and Th2-lymphocytes produce and secrete IL-5, IL-13 IL-17 and GM-CSF, 
resulting in recruitment of inflammatory cells (basophils, eosinophils and neutrophils) which are 
responsible for the LAR 2-6 hours later (fig 1.2) 21.  
The inflammatory cells secrete products (cytokines, enzymes, metabolites and growth factors (IL-5, IL-
13, TGF-β and matrix metalloprotease 9 (MMP9)), that damage and act on the surrounding tissue such 
as fibroblasts, smooth muscle cells, neuronal cells and epithelial cells 40. Once established, repetitive 
cycles of tissue damage and inflammatory-cell recruitment cause persisting chronic airway 
inflammation, resulting in repetitive phases of tissue destruction and tissue repair, leading to structural 
changes of the airway, named airway remodeling. Airway remodeling is characterized by airway wall 
thickening, subepithelial thickening from increased deposition of extracellular matrix proteins (ECMs) 
such as collagens, proteoglycans and glycoproteins, increased vascularity, goblet cell hyperplasia, airway 
smooth muscle cell hyperplasia and hypertrophy and epithelial hypertrophy resulting in a lower baseline 
lung function 41–44.  
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Airway remodeling is traditionally recognized as a marker of a long-standing chronic disease, yet there 
are some suggestions that it can be an early feature of the disease. Airway remodeling was for instance 
found in children without the evidence of Th2 inflammation, suggesting that airway remodeling can 
occur independently of Th2 inflammation. This finding was strengthened by the observation that 
epithelial damage, thickening of basement membrane, angiogenesis already was found in 4 years old 
asthmatic children 42. These observations are supported by the fact that, IL-33, activin A, endothelin-1 
and IL-25, secreted by epithelium cells, may drive airway remodeling and AHR 43,45,46. Although in certain 
cases airway remodeling can be dissociated from airway inflammation, there is a close link between 
airway remodeling and the loss in lung function seen in asthma 43,44.  
The described Th2 mediated allergic immune response of asthma can be inhibited by the Treg cells. Treg 
cells play an important role in maintaining a balanced adaptive immune response by the production of 
IL-10 and TGF-β. A defect that effects the Treg cell number and/or function disrupts this balance, leading 
to a lower number and impaired suppressive activity of Treg cells, which will finally stimulate ongoing 
infiltration of immunological/inflammatory cells, thereby contributing to the pathogenesis of allergic 
asthma 16,47. 
In addition to the Th2 response, DC polarize CD4+ T (Th) cells into Th1 cells via the production of IL-12. 
Together with innate lymphoid cells type 1 (ILC1), Th1 cells secrete tumor necrosis factor (TNF)-α, IL-2 
and interferon (IFN)-γ (fig 1.2). Th1 cells are involved in patients having a disease onset in adulthood, 
which is associated with a predominant neutrophilic lung inflammation and a severe asthmatic outcome 
38,48. 
2.2 Neural mechanisms 
Besides the interplay between innate and adaptive immune system, the nervous system also regulates 
asthmatic responses. Upon irritant signals (cigarette smoke, vehicle exhaust and air pollutants), sensory 
nerves become activated via transient receptor potential (TRP) channels, resulting in coughing, mucus 
production, bronchoconstriction, vasodilatation and dyspnea 49. In addition, stimulated sensory nerves 
will release tachykinins (substance P (SP), neurokinin (NK) A and NKB) and calcitonin gene-related 
peptide (CGRP) from sensory nerves terminals. These neuropeptides exert many inflammatory and 
immune-modulatory effects such as smooth muscle contraction, submucosal gland secretion, 
vasodilatation, increase vascular permeability, stimulation of mast cells, T- and B- lymphocytes and 
macrophages, chemo-attraction of eosinophils and neutrophils and vascular adhesion of neutrophils, 
summarized as neurogenic inflammation 50,51.   
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3. Work related asthma 
Work related asthma encompasses both occupational asthma (OA) and work exacerbated asthma 
(WEA) (fig 1.4). Work exacerbated asthma is characterized by worsening of pre-existing asthma due to 
workplace related exposures, while occupational asthma is due to exposure to a specific causal agent 
present in a particular work environment and not to stimuli encountered outside the workplace 52. Work 
related asthma is increasingly recognized as the most common cause of occupational lung diseases and 
is believed to cause up to 15-25% of the cases of adult onset asthma 53. The clinical manifestations are 
similar to those found in non-occupational asthma, with varying degrees of disease severity. Mild cases 
are recognized by episodic dry cough, chest tightness, and increased breathing effort at the workplace, 
while severe cases are recognized by wheezing, cough, chest tightness, shortness of breath, and 
dyspnea that persist away from the work environment 52,54.  
 
Fig 1.4: Subdivision of work related asthma 53. 
Occupational asthma can be classified, based on the underlying pathogenesis and presence of a latency 
period, into two subtypes namely irritant-induced asthma and immune-mediated asthma 52. Irritant-
induced asthma occurs after exposure to irritants (such as ammonia or chlorine) at the workplace in the 
absence of sensitization. This subtype can be subdivided into a severe form which can occur within 24h 
after a single exposure to high concentrations of an irritant, named ‘reactive airway dysfunction 
syndrome’ (RADS). On the other hand, there is also a delayed onset of irritant-induced occupational 
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asthma, which may occur after multiple exposures to smaller doses of irritants over days, weeks, or 
months 53. Immune-mediated occupational asthma develops after an asymptomatic latent period 
(weeks to years), during which allergic sensitization develops (fig 1.4). 
To date, more than 400 agents are recognized as trigger of immune-mediated OA and the list continues 
to grow 53. Agents capable of inducing immune-mediated OA can be classified according to their 
molecular weight: high molecular weight (HMW) (>10KD) proteins or low molecular weight (LMW) 
chemicals (<2KD) (Table 1.2) 53. HMW agents include compounds in flour (cereals), seafood, latex, 
enzymes (derived from plant, animal and microbial), house dust mite and allergens of laboratory animals 
and shellfish, which induce immune-sensitization via classical IgE-mediated mechanisms. LMW 
compounds are typically small highly reactive chemical molecules. These small molecules are non-
immunogenic in their native state, yet when they bind to endogenous proteins (such as albumin, keratin 
or tubulin) stable ‘hapten-protein’ conjugates are formed. Similar to HMW, some LMW chemicals (such 
as platinum salts, reactive dyes, acid anhydrides and some wood dusts) are associated with the 
production of specific IgE antibodies; however, several chemical sensitizers (such as isocyanates, 
persulphate salts and aldehydes) induce OA with an unclear role for IgE. The immunological mechanisms 
of this phenotype of asthma are still poorly understood 55.  
Table 1.2: Cross-sectional studies of workers exposed to occupational asthmogens, from Jaakkola et al. 56. 
Exposure/ Industry/Occupation Exposure Before Diagnosis (months) 
Prevalence of Work-
Related Asthma Number Studied 
High-molecular-weight agents 
Enzymes/detergent 
Guar gum/carpet industry  
Snow-crab/food processing 
Laboratory animal workers 
Flour/bakery workers 
Latex/hospital workers 
 
Intermittent 
Up to 108 
Several months 
26 
12 
120 
 
50 
23 
21 
7 
6 
2 
 
98 
162 
303 
238 
264 
289 
Low-molecular-weight agents 
Platinum refinery 
Colophony/ electronic plants 
Isocyanates/ secondary industry 
Spiramycin/ pharmaceutical 
Plicatic acid/ forestry workers 
 
12-24 
24 
54 
n/a 
n/a 
 
54 
22 
20 
9 
4 
 
91 
924 
51 
51 
625 
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3.1 Diagnosis 
Occupational asthma has significant health consequences for affected patients, but also social-
economic impacts for workers, their employers and wider society. Therefore, an accurate diagnosis is 
very important. Missing diagnosis of OA leads to continued exposure to a causative agent and worsening 
of the disease outcome. Various tests are described to make a valid diagnosis for OA.  
Depending on the clinical and occupational history of the patient, the physician can determine whether 
the symptoms improve outside the workplace. However, to confirm that the patient has asthma, a 
bronchial provocation test is performed to determine AHR to non-specific stimuli by measuring lung 
function after inhalation of bronchoconstrictive agents, such as histamine or the non-selective 
muscarinic receptor agonist methacholine. Taking into account that sometimes AHR rapidly improves 
and even becomes absent a few days after cessation of exposure to the causative agent, this test is 
insufficient to diagnose OA.  
To increase the specificity of the assessment of AHR, this measurement is complemented with an 
immunological skin prick test and assessment of serum-specific IgE antibodies to demonstrate IgE 
mediated sensitization. Since several LMW agents induce OA in an IgE independent manner, this test is 
inconclusive 57. Consequently, specifically for LMW compounds, there is a strong need for developing 
additional reliable markers. Several studies focused on identifying environmentally responsive genes to 
recognize susceptible subpopulations. Specifically for diisocyanate-induced asthma, genetic 
susceptibility markers placed in the human leukocyte antigen (HLA)-region and CTNNA3 (a single 
nucleotide polymorphism of the alpha-T-catenin) are identified. HLA class 2 molecules are crucial in 
antigen recognition during Th2 inflammation. Therefore, HLA can be plausible candidate genes involving 
specific immunological responses and contributing to individual susceptibility in OA. Several studies 
suggested that HLA alleles (HLA-DQB1*0503, HLA-DQB1*0201-0301, HLA DQA1*0104, DRB1*15-
DPB1*05, HLA-DRB1*1501, HLA-DQB1*0602, HLA-DPB1*0501) are associated with an increased risk of 
TDI-OA. On the other hand, HLA alleles HLA-DQB1*050, HLA-DQA1*0101 and HLA-DQB1*0501 seems 
to have a protective effect against TDI-OA 58. 
To demonstrate that the symptoms are related to the workplace, lung function is measured on both 
workdays and free days. Serial measurements of peak expiratory flow (PEF) are an effective manner of 
monitoring changes in pulmonary functions during the day. These self-measurements can be 
complemented with serial measurements of non-specific AHR and airway inflammation by measuring 
exhaled nitric oxide and evaluation of sputum eosinophils 57,59. 
To identify the causal agent responsible for OA, a specific inhalation challenge (SIC) test is used. During 
a SIC, the patient is exposed to the suspected agent in a controlled exposure room to investigate 
reactivity of the airways to the specific agent 57. A drop of at least 15% in FEV1 after a specific challenge 
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is considered as a positive diagnostic SIC test. Although the SIC test is the gold standard for the diagnosis 
of OA it has several limitations namely, it is not easy to perform, it is time consuming, costly, carries 
some risk for the patient and should only be performed in specialized centers 60,61.  
3.2 Prevention and management 
Often, decisions made in the management/prevention of OA have a significant social, financial, and 
psychological impact on workers and their families 61.  
Generally, there are three main preventive steps. The first step includes education regarding 
occupational asthma, safe work practices and avoidance of known sensitizer agents. This can be 
achieved by replacing sensitizing agents with non-sensitizers: e.g. replacing rubber latex gloves with 
nitrile gloves or volatile chemicals with less volatile chemicals. When replacement is not possible, 
reducing/eliminating exposure to the sensitizer is recommended (personal protective equipment and 
hygiene measures). As early diagnosis results in a better disease outcome, the secondary prevention 
strategy is the early detection of OA. This can be obtained by periodic monitoring using respiratory 
questionnaires, spirometry, immunologic tests and continued education regarding occupational asthma 
symptoms and signs. The third step is prevention/appropriate treatment of occupational asthma 53,55. 
The main treatment for OA is identical as treatment of allergic asthma: long-acting β2 agonists and 
inhaled corticosteroids. However, as the underlying mechanisms of OA is not yet fully clarified, 
especially for LMW compounds, it is still a challenge to recommend the appropriate treatment. As a 
consequence, long-term deterioration cannot be prevented 39,41,46,47. 
The management of OA is not different from the management of non-work related asthma, except the 
reduction/elimination of the causal exposure. As persistent exposure to a causative agent after 
diagnosis of OA leads further to a worse clinical outcome including fatal asthma exacerbations, complete 
cessation of further exposure to the causative agent results in the best clinical outcome 60,61. This can 
be achieved by relocation of the patient to a new job in the same plant or in another site where there 
is no exposure to the causative agent or early retirement. However, only 32% recover completely from 
asthma symptoms, even after cessation of exposure to the causative agent 53,55,62.  
In the case of job change, it is important that the physicians are aware of the impact of the decisions 
made for the patient suffering from OA. Almost 50 % of the patients have depression and anxiety after 
leaving their job and are concerned about the economic consequences after being identified with OA. 
42% to 78% of the workers diagnosed with OA have significant loss in income after changing their job 
61. Because of these concerns, certain workers choose to be remained exposed. For some patients, it is 
sometimes even not possible to be relocated to a job free from exposure to the causative agent. In this 
case a worker’s compensation claim should be initiated to cover lost wages and medical expenses 53. In 
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cases when patients are unable or unwilling to change their jobs, it is important to minimalize the 
exposure to the causative agent by personal protective equipment such as proper respiratory and skin 
protection along with hygiene measures such as lowering the dose below the limit values by improving 
ventilation. However, these measures are only effective for OA caused by HMW sensitizers. For most of 
the LMW agents, such as isocyanates, these measures are still inadequate in preventing new asthma  
cases 61.  
3.3 Diisocyanates 
As shown in table 1.2 diiscocyanates are a commonly identified cause of LMW-induced OA worldwide. 
5-30% of the workers exposed to isocyanates are at risk to develop the disease 63,64. Diisocyanates are 
LMW chemicals and are characterized by two -N=C=O groups which exhibit strong chemical reactivity, 
making isocyanates highly reactive chemicals 65. These highly reactive -N=C=O groups allow them to 
undergo direct polymerization reactions with alcohols (such as polyols) to form polyurethanes 66. The 
most important commercial aromatic diisocyanates are toluene diisocyanate (TDI) and methylene 
diphenyl diisocyanate (MDI), and the most important commercial aliphatic isocyanate is hexamethylene 
diisocyanate (HDI) (fig 1.5). MDI and TDI together account for more than 90% of the global isoscyanate 
market, and their annual production exceeds 4 million tons 64,67. TDI and MDI are used to manufacture 
products such as flexible and rigid foams, adhesives and sealants, such as foam rubber cushions, 
dashboards and finished coatings. Furthermore, MDI is increasingly used in the building industry, foam 
mattresses and footwear 68. The aliphatic isocyanate HDI is primarily used in coatings and paints. Due 
to its unique physical properties, MDI has become the most abundantly produced and consumed 
diisocyanate.  
TDI, commonly used as a mixture of 2,4 and 2,6 isomers (80:20), is a colorless mixture and is highly 
volatile at room temperature, while MDI is a solid and needs to be heated before vapors are released 
68. Despite variable physical and chemical properties, including vapor pressure, solubility, and size, all of 
 
2,6 Toluene diisocyanate 
 
 
 
 
2,4 Toluene diisocyanate 
 
 
 
4,4’ Methylene diphenyl diisocyanate Hexamethylene diisocyanate  
Fig 1.5: Structures of diisocyanates.   
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the major monomeric, prepolymeric and polydiisocyanate species are capable of inducing asthma in 
exposed workers 69. 
High acute irritant exposure to diisocyanates is known to cause RADS and irritant-induced asthma. 
However, besides the acute toxicity, isocyanates are potent immune sensitizers. After sensitization, low 
airborne concentrations can elicit an asthmatic reaction.  
3.3.1 Immune sensitization 
To induce an immune response, LMW compounds can act as haptens that react with alcohols, phenols, 
amines and thiols of endogenous proteins. Diisocyanates mainly conjugate in the lung with proteins 
such as tubulin and actin. Other skin and lung proteins and peptides are glutathione-S-transferase (GSH), 
keratin and actin. After binding with endogenous proteins, diisocyanates are recognizable by the 
immune system 63,67. MDI and TDI can first bind to the tri-peptide, γ-glutamyl-cysteinyl-glycine, also 
known as GSH, in the exposed tissue, which is followed by a GSH-mediated transfer of MDI or TDI into 
the blood stream where it can bind to specific lysines (Lys) residues of the highly present protein human 
serum albumin (HSA) 70,71. In a liquid phase, TDI binds to 34 of the 59 lysine residues on HSA, while MDI 
only binds to 19 lysine residues on HSA (fig 1.6) 67. However, using TDI in a vapor phase, less binding 
sites are found on HSA 64. Additionally, different binding sites on HSA are detected between isomers 
2,4- and 2,6-TDI. The 2,4-isomer has a higher reactivity to albumin resulting in more bindings compared 
to the 2,6-isomer 72. The increasing binding capacity of TDI compared to MDI can be attributable to the 
increased reactivity of the functional isocyanate groups: the electron withdrawing character of the 
second -N=C=O group on the aromatic ring of TDI significantly increases the reactivity of the first 
isocyanate 67. It has been observed that TDI can conjugate to serum albumin in two different forms. The 
first results from hydrolysis of one isocyanate to a primary amine, whereas the second isocyanate 
moiety undergoes nucleophilic addition to the protein. The second is the result of both isocyanates 
undergoing nucleophilic addition to the protein, resulting in an intramolecular crosslinking. This is often 
seen when two lysines are located in close proximity, like the four dilysine motifs in HSA. Rarely, 
intermolecular cross-linking of two protein molecules can be caused by one TDI. 64. The binding of 
isocyanates on HSA changes its conformation and charges, resulting in an antigenic product 73. 
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 Fig. 1.6: Front (left) and rear (right) projections of human albumin. Conjugation sites for MDI (A) and TDI (B) are highlighted in red. From Justin M. Hettick and Paul D. Siegel 67. 
As HSA is the major diisocyanate adduct in the blood, diisocyanate-albumin reaction products in the 
blood stream may serve as biomarkers. Artificially prepared diisocyanate protein conjugates have been 
used to develop in vivo monoclonal antibodies toward isocyanates, with the aim to identify different 
diisocyanate-protein adducts in the blood serum of isocyanate exposed workers 63,74–76. In addition, to 
confirm immune sensitization, diisocyanate-protein conjugates have been developed with the aim to 
detect isocyanate specific immunoglobulins in serum of exposed workers. These studies mainly focused 
on HSA, identified as the major target for inhaled isocyanates.  
It needs to be taken into account that the antigenic product resulting from artificial isocyanate-protein 
conjugation are influenced by the production method used (liquid phase or vapor phase) and molar 
ratio 64,73,75,77–80. Preparing biologically relevant hapten-protein conjugates is technically difficult and by 
using inappropriate conjugates, specific antibodies will be missed. Therefore, it is necessary to be able 
to mimic the real life in vivo micro environment 81.  
3.3.2 Skin-lung interaction 
In the past, inhalation has long been considered as the primary route of isocyanate exposure, induction 
of sensitization and asthma 82. Consequently, many measures were taken to decrease the airway 
exposures to isocyanates, such as increased use of the less-volatile isocyanate MDI, improved hygiene 
practices such as personal projective equipment and reducing TDI airborne concentration. In 2016, the 
American Conference of Governmental Industrial Hygienists (ACGIH) proposed a threshold limit value 
(TLV, 8h time weighted average) of 0.001 ppm and 0.005 ppm for the short time exposure limit (STEL, 
15 min timed weighted average) 83. In contrast, in Belgium the TLV and STEL are still 0.005 ppm and 
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0.037 ppm, respectively. Yet, despite the low airborne isocyanate concentrations, asthma continues to 
occur 82. 
To date, a growing body of evidence exists that skin exposure is an efficient route to induce sensitization, 
with subsequent inhalation challenge resulting in an asthmatic response 82. Depending on the type of 
isocyanate or application method, isocyanate exposure can occur in different forms (vapors, aerosols or 
liquids). The introduction of less volatile forms of isocyanates, such as MDI, reduced the risk of 
respiratory exposure but not necessarily skin exposure. Skin exposure can result from deposition of 
aerosols and/or absorption of vapors of isocyanate end uses such as spraying and application of foams 
and adhesives. Furthermore, workers can come into contact via the skin trough accidental spills, cleanup 
and contact with contaminated equipment 82. In addition, Isocyanates are commonly mixed with other 
compounds such as polyols, catalysts and blowing agents which affect their reactivity and skin 
absorption. Impairment of the skin barrier, caused by mutations in the skin protein filaggrin, 
overexpression of TSLP, frequent use of soaps and cleaners, additional exposure to other skin irritants, 
physical trauma, heat and low humidity and glove use, can facilitate allergen penetration and systemic 
sensitization to chemicals 84.  
Biomarkers such as urinary metabolites (toluenediamine, methylenediamine and hexa- 
methylenediamine) can be useful indicators for isocyanate exposure, but are not able to distinguish 
between skin and respiratory exposure. Specific isocyanate skin exposure can be identified by skin tape 
strips 84,85. Tape-strip sampling is a removal technique in which the stratum corneum of the skin is 
collected using specific tape, after exposure in the work place. Subsequently, chemical agents present 
on the tape are analyzed and quantified using liquid chromatography/mass spectrometry (LC-MS), and 
are used as a proxy to assess possible skin exposure 86. 
3.4 Animal models of chemical-induced asthma 
The pathology of asthma is complex, heterogeneous and in many instances poorly understood 87. 
Unraveling the cellular and molecular mechanisms of asthma is not fully possible in human 88. As 99% 
of the genes are shared between mice and human, the mouse has become the most widely used species 
to study the pathophysiology of asthma 89,90. Mice are easy to breed, maintain and handle. Additionally, 
a wide array of specific reagents to analyze cellular and mediator responses are available together with 
the availability of genetically engineered transgenic mice for modelling airway disease 91.  
Due to the complexity of asthma, it is unlikely that a single animal model can mimic all of the morphology 
and functional features of the chronic human disease 92. Therefore, mouse models need to be refined 
so that they are able to reflect clinical findings of disease characteristics, pathways and specific 
phenotypes 93. As mice do not spontaneously develop asthma, artificial asthmatic-like reactions have to 
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be induced to investigate the disease 92. To mimic asthma-like reactions, mice first need to be sensitized 
to an antigen of interest (via intra peritoneal injections (i.p), skin exposure or airway exposure) followed 
subsequently by airway challenging (intranasal, oropharyngeal, intratracheal instillations or aerosols) 88. 
The disease outcome of asthma models is influenced by the compound, dosing, route and schedules of 
sensitization and challenge, and the choice of mouse strain 92.  
 Compounds 
Asthma research primarily focused on HMW allergens, which are frequently associated with allergic 
asthma such as HDM, ragweed extracts, aspergillus, ovalbumin (OVA) and cockroach antigens 93. Less 
commonly, despite being also an important cause of OA, research focused on animal models of asthma 
induced by LMW compounds. In the case of LMW compounds, most animal research focused on 
diisocyanates, more specifically TDI, MDI and HDI 94–101. 
 Treatment protocols 
To mimic the wide variety of characteristics of asthma, both acute and chronic mouse models were 
introduced. After sensitization, the acute challenge mouse models reproduce many key features of 
asthma such as early ventilatory response, AHR, airway inflammation and elevated levels of IgE. 
Nevertheless, because of the short-term nature of acute models, many of the characteristics observed 
in chronic human asthma such as chronic inflammation of the airways and airway remodeling remain 
absent. Furthermore, in acute models, the key features such as airway inflammation and AHR appear to 
resolve within days/few weeks after the final allergen challenge. To develop airway remodeling and 
persistent inflammation and AHR, chronic mouse models were introduced 92. Yet, also inflammation and 
AHR can disappear during chronic challenge protocols 102. 
Inhalation, intra-tracheal, oropharyngeal or intranasal instillations are widely used to administer agents 
to the respiratory tract. Inhalation is the most natural way of exposure, but it is technically demanding, 
expensive and time-consuming. Intranasal applications are easy to perform and can be repeatedly used 
in a short time period; however the instilled volume, degree of anesthesia and vehicle (aqueous or non-
aqueous) heavily influence the distribution between the upper and lower airways. Intra-tracheal 
instillation bypasses the nose by placing a catheter into the trachea, which allows administration of 
exact amounts of the agent into the lung. However, it requires general anesthesia and can cause injury 
to the trachea, certainly after repeated use. Therefore, alternatively, an oropharyngeal challenge has 
been introduced, in which the liquid is pipetted onto the back of the tongue. Both intra-tracheal and 
oropharyngeal challenge techniques have been shown to uniformly distribute agents into the lung 103–
106. However, by placing the pipette on the tongue during the oropharyngeal challenge, the compound 
goes not consistently to the lung, resulting sometimes in gastro-intestinal exposure. Therefore, an 
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endotracheal instillation technique is introduced as an alternative method. During this instillation, mice 
are held vertically and the pipette is placed just above their vocal cords preventing swallowing of the 
agent.  
In an attempt to develop mouse models of chemical-induced asthma, different routes of sensitization 
have been described. Airway exposure (inhalation and intranasal application) has been successfully used 
in the sensitization and subsequently elicitation phase in isocyanate-induced asthma 95,107,108. 
Nevertheless, as already discussed in isocyanate-induced asthma, skin exposure is also an important 
route of sensitization. Therefore, in many models the sensitization phase was based on skin exposure 
(topically or subcutaneously), subsequently followed by an elicitation reaction using airway exposure 94–
96,101,103,107,109–113. Ban et al., evaluated several sensitization protocols (inhalation exposure, intra-
tracheal instillation and skin application) and demonstrated that skin exposure followed by airway 
exposure resulted in the most pronounced systemic Th2-dominated response 98. However, it should be 
taken into account that the used sensitization concentrations influence the lung response. It has been 
shown that high skin exposure abolish the asthmatic features 96,101,114.  
 Choice of mouse strain 
The genetic background of different mouse strains has a large influence on the phenotypical outcome 
of TDI-induced asthma. In a well-defined acute mouse model of chemical-induced asthma, De Vooght 
et al. showed that in seven different mouse strains, of which three were Th2-prone strains (BALB/c, BP2 
and A/J) and four were Th1-prone strains (C57Bl/6, DBA/2, AKR and CBA), there were different 
responses in AHR, BAL cellular inflammation, cytokine profile, and serum antibody levels. The AHR 
differed even in baseline level, which can be due to the differences in alveolar size, lung volume, elastic 
recoil properties and airway structure between the different mouse strains 115–117. In general, the 
features of human OA are best mimicked in BALB/c mice 118. Using different treatment protocols and 
mouse strains, several phenotypes of occupational asthma can be developed.  
3.4.1 TDI-induced mouse models of asthma 
Our lab developed an acute mouse model of chemical-induced asthma using TDI as model agent. In this 
mouse model, mice are dermally sensitized on the dorsum of both ears with TDI on days one and eight 
resulting in an increased number of T- and B- cells in the auricular draining lymph nodes. The increase 
of T cells is associated with an increased release of Th2 cytokines (IL-4, IL-13, IL-10) and Th1 (IFN-γ) 
cytokine, along with changes in proteome 119. A subsequent TDI airway challenge on day 15 results in a 
reproduction of important features of chemical-induced asthma such as early ventilatory response, non-
specific airway hyperresponsiveness and airway inflammation, characterized by mainly neutrophils but 
also eosinophils 24h after the challenge 114. 
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This mouse model showed the ability to distinguish respiratory sensitizers (trimellitic anhydride (TMA)) 
from dermal sensitizers (dinitrochlorobenzene (DNCB)), along with differentiating chemicals for their 
sensitization and asthmogenic potentcy 120. Ammonium persulfate showed a positive asthma-like 
response, which was not the case for methylisothiazolinone 121,122. Furthermore, this mouse model was 
used to test cross-reactions between two related chemicals, toluene diamine (TDA) and TDI. TDA was 
not able to induce an asthmatic response and there was no cross-reaction with TDI 123. 
Besides validation of chemicals, our and other mouse models are used to study the underlying 
pathophysiology of chemical-induced asthma. Many features of diisocyanate asthma are similar to 
atopic asthma such as airway inflammation characterized by activated CD4+ T cells, eosinophils, mast 
cells, airway remodeling and increased levels of Th2 cytokines IL-4 and IL-5. Nevertheless, there are 
some differences. Diisocyanate-induced asthma is characterized by a prominent airway neutrophilia, 
increased IL-8, TNF-α, monocyte chemoattractant protein (MCP)-1 production and a mixed Th1/Th2 
cytokine response. Furthermore, CD8+ T cells seems to be more involved than CD4+ T cells. Additionally, 
the prevalence of diisocyanate specific IgE antibodies are low and the disease is not associated with 
atopy 124. However, as the exact role of these immunological responses are not yet fully delineated, 
mouse models have been developed to study the underlying mechanisms. 
Lymphocytes and associated cytokines in chemical-induced asthma 
Both animal and human studies showed an increase of both CD4+ and CD8+ lymphocytes in diisocyanate-
induced asthma 125. To assess the role of lymphocytes in chemical-induced asthma, various mechanistic 
studies have been performed in different diisocyanate-induced mouse models. Already from 1996, 
Scheerens et al. performed an adoptive transfer experiment where lymphocytes were transferred from 
TDI treated mice into naive mice resulting in AHR, without airway inflammation, after a TDI challenge 
126. Matheson et al. demonstrated that in both transgenic CD4+ or CD8+ knockout (KO) mice, the AHR 
and airway inflammation were reduced after sub chronic TDI exposure 110. Furthermore, they showed 
that adoptive transfer of purified T-, or B- cells from sub-chronically exposed mice into naive mice 
resulted in AHR after TDI challenge 95. More recently, our lab demonstrated an abolished asthmatic 
response in severe combined immunodeficient (SCID) mice, who lack mature lymphocytes, 
demonstrating the crucial role of these lymphocytes 111. To establish the role of these lymphocytes, 
naive mice became passively sensitized via an adoptive transfer technique using, compared to previous 
described adoptive transfer studies, very low numbers of lymph node cells from TDI-sensitized mice, 
resulting in AHR and airway inflammation after an airway challenge. More specifically, transferring B-
lymphocytes from lymph nodes of TDI-sensitized mice in to SCID mice, resulted in airway hyperreactivity 
and airway inflammation after a TDI challenge, demonstrating that B-lymphocytes may play an 
important role in asthma without the presence of T lymphocytes 127. Additionally, proteomic studies 
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performed by Haenen S et al. demonstrated that sensitization changed the expression of several B cell 
proteins involved in the recruitment of neutrophils, antigen presenting capacities and the production 
of immunoglobulins 128.  
Both animal and human studies of diisocyanate-induced asthma, demonstrated the presence of both 
Th2 and Th1 associated cytokines 95,125. To evaluate the contribution of those cytokines in diisocyanate-
induced asthma, several animal studies with exposure to HDI have been performed. Mice deficient in 
cytokine IL-4, IL-13, IL-4/IL-13 or IFN-γ showed a reduced AHR; moreover, the least effect on AHR was 
found in the IL-4 deficient mice. BAL cell infiltration was decreased in mice deficient in IL-4 or IL-13 and 
particularly in the combined IL-4/IL-13 deficient mice. Recently, our lab showed that by systemically 
blocking IL-13, AHR is diminished in a paucigranulocytic phenotype of TDI-induced asthma. IFN-γ KO 
mice showed only a slight decrease in BAL cell numbers 110. TNF-α receptor (TNFR) knockout and anti–
TNF-α antibody–treated mice showed that TNF-α played an important role in AHR, airway inflammation 
and dendritic cell migration to the draining lymph nodes 113.  
Immunoglobulins in chemical-induced asthma 
In the majority of people with diisocyanate-induced asthma, allergen-specific IgE cannot be identified 
129. Additionally, atopy is not considered as a risk factor for diisocyanate-induced asthma 130. 
Nevertheless, Lavaud et al. described an improvement of FEV1 after treatment with omalizumab (anti-
IgE therapy) in two atopic diisocyanate-asthmatic patients having very high levels of total IgE 131. 
Furthermore, IgG are found in diisocyanate workers without asthmatic symptoms, suggesting that they 
are an indicator of exposure rather than disease 95. Although IgE is only found in very low proportions 
of patients of diisocyanate asthma, total IgE and IgG are easily detected in several mouse models of 
diisocyanate-induced asthma 95,96,103,111,112,114,132. In mice, IgE and IgG1 antibodies are associated with 
Th2 cytokine response, while IgG2a antibodies are associated with Th1 cytokine response 110.  
To examine the role of humoral immunity in TDI-induced asthma, several experiments have been 
performed. Serum from sub-chronically exposed mice passively transferred into naive mice resulted in 
an increase of airway inflammation, and AHR 24 post TDI challenge 95. In an acute mouse model, De 
Vooght et al. transferred serum from TDI treated mice into naive mice which also resulted in airway 
inflammation and AHR 127. On the other hand, there are indirect evidences showing a weak association 
between IgE and asthma. By decreasing the sensitization concentration, and consequently lowering 
serum IgE, AHR and airway inflammation increased after an airway challenge 96,101,114. Vanoirbeek et al. 
showed that by prolonging the time between sensitization and a single challenge, the AHR and airway 
inflammation decreased despite that the IgE, IgG1 and IgG2a concentrations remained unchanged 133.  
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The role of IgE in isocyanate asthma remains an important but controversial topic. There are several 
explanations why isocyanate specific IgE are only found in a very low amount of patients. It is possible 
that isocyanate specific IgE are not detectable because of wrong forms of ‘isocyanate antigen’ in the 
immunoassay. Isocyanate-self protein reaction products are extremely diverse, and their antigenicity 
may differ significantly depending upon the reaction conditions under which they are formed. 
Furthermore, 30 days away from exposure, IgE serum levels may decrease and become undetectable 
129.  
Eosinophils and neutrophils in chemical-induced asthma 
Diisocyanate-induced asthma is a phenotype of asthma characterized by a predominantly neutrophilic 
inflammation, and to a less extent by an eosinophilic inflammation 103,124,134. Predominantly neutrophilic 
airway inflammation is often associated with severe asthma and has typically an onset of disease in 
adulthood and is less corticosteroids responsive 48. Moreover, neutrophils are the first cells that migrate 
toward the site of inflammation 135. De Vooght et al, studied the role of both neutrophils and eosinophils 
during the effector phase in an acute mouse model of chemical-induced asthma. In that study, depletion 
of both cells abolished AHR and lung epithelial damage, suggesting that both neutrophils and 
eosinophils are key cellular players in inducing asthma in a mouse model of chemical-induced asthma 
136. Furthermore, it has been shown that toluene diisocyanate exposure induces airway inflammation 
via the activation of transient receptor potential melastatin 8 (TRPM8) 137. 
Dendritic cells in chemical-induced asthma 
Dendritic cells play a role in both the sensitization and effector phases of asthma. Several studies suggest 
an involvement of dendritic cells in the pathophysiology of diisocyanate-induced asthma. Twenty years 
ago, Ban et al. already showed an accumulation of DC in lung associated lymph nodes after inhalational 
TDI exposure 138. In 2002 Matheson showed, using TNF-α KO mice, that dendritic cells migrate within 
24h to the cervical lymph nodes in a TNF-α dependent manner after intranasal instillation of TDI in 
subcutaneously sensitized mice 113. Recently, Nayak et al. showed that during TDI skin sensitization, TDI-
haptenated proteins are co-localized with antigen presenting cells in the skin and local draining lymph 
nodes 139. Yet, the involvement of the different DC subpopulations has not yet been studied in chemical-
induced asthma; this in contrast to HMW compounds HDM and OVA.  
Sensory nerves and neuropeptides in chemical-induced asthma 
Several studies concerning the role of sensory nerves and neuropeptides in chemical-induced asthma 
have been performed. In the past Scheerens et al. showed the involvement of tachykinin neuropeptides 
(including substance P (SP), neurokinin A (NKA) and calcitonin-gene-related peptide) and their receptor 
neurokinin 1 receptor (NK1R), during the effector phase of TDI-induced OA 140. Recently, Devos et al, 
Introduction 
24  
showed that TDI directly and indirectly activates TRPA1 and TRPV1, respectively, resulting in the release 
of the tachykinin neuropeptide substance P. Moreover, Devos et al. showed that in TRPA1, TRPV1, 
substance P receptor NK1R and mast cells are crucial in inducing AHR 141. Tachykinins released after 
activation of TRPA1 and TRPV1, do not act directly on the tracheal smooth muscle cells. In fact, 
tachykinins probably induce indirectly tracheal hyperreactivity by the induction of mast cell 
degranulation, as their NK1 receptor is upregulated on mast cells during inflammation, leading to the 
release of histamine and other inflammatory mediators 140,142. These inflammatory mediators can 
directly activate nerve cells in the airways and thereby induce nerve depolarization. This hypothesis was 
strengthened by Devos et al., who showed an abolished AHR response in mast cell deficient mice 141. 
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Rationale: 
Occupational asthma (AO) is one of the most common work-related respiratory diseases in 
industrialized countries. Low molecular weight (LMW) agents like diisocyanates are a major cause of 
OA. The mechanisms by which these chemicals induce OA are still not fully understood. They differ from 
high molecular weight (HMW) allergens since they first need to bind endogenous proteins before they 
are recognizable by the immune system. Moreover, in several cases no specific immunoglobulins (Ig)E’s 
can be identified. Although HMW and LMW seems to be phenotypically alike, the mechanisms do differ. 
In this thesis, we focused on the mechanistic insight of LMW induced asthma 
 
Aims: 
1. Study the cross-reactivity between the two most prominent used diisocyanates (chapter 3) 
We evaluated the cross-reactivity between the most prominent used diisocyanates toluene 
diisocyanate (TDI) and methylene diphenyl diisocyanate (MDI). Human and animal studies showed that 
both diisocyanates affect the respiratory system and have common bindings to lysine residues on 
human serum albumin (HSA). Moreover, both diisocyanates are often used in the same plants and 
sometimes even together in the same production process. Therefore, it seems likely that cross-reactivity 
will occur between both chemicals in exposed workers. To investigate the cross-reactivity between TDI 
and MDI, we dermally sensitized mice with TDI and gave them an airway challenge with MDI and vice 
versa.  
2. Study dendritic cells in different phenotypes of chemical-induced asthma (chapter 4 and 5) 
Asthma is driven by genetic and environmental factors, making it a complex and heterogeneous disease 
resulting in different clinical outcomes, also called phenotypes. Due to the complexity and 
heterogeneity of asthma, it is unlikely that one single mouse model is capable to mimic all the features 
of human asthma. Until now, we mainly performed studies using an acute mouse model, consisting of 
a sensitization phase followed by only one single airway exposure. Yet, due to the short-term exposure, 
many of the features of chronic human asthma, such as chronic inflammation and airway remodeling 
could not be investigated in this model. To induce severe inflammation and airway remodeling we 
developed two different exposure models. Both exposure models represent two different phenotypes 
of chemical-induced asthma. As dendritic cells (DC) are crucial during the sensitization and elicitation 
phase of Th2 mediated allergic asthma, we investigated, for the first time, the presence of DC in the 
lungs of both exposure models.  
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 2.1  Development of a chronic intranasal mouse model (chapter 4) 
Based on a chronic house dust mite model (HDM), we developed a chronic mouse model using TDI as 
model agent. In this chronic model, we aimed to induce AHR, severe airway inflammation and airway 
remodeling. Furthermore, we wanted to investigate the presence of DC in the lung of this asthma 
phenotype. To achieve this aim, we dermally treated mice on the dorsum of both ears on days one and 
eight followed by five intranasal exposures each week, for five consecutive weeks.  
 2.2  Development of a sub-chronic oropharyngeal mouse model (chapter 5) 
The previous described chronic-nasal mucosa exposure protocol showed pronounced AHR, but was not 
accompanied with airway inflammation nor airway remodeling. This chronic model reflects rather a 
paucigranulocytic phenotype of chemical-induced asthma, a phenotype where sputum cell counts are 
within the normal range. With the aim to induce pronounced airway inflammation and airway 
remodeling, and consequently investigate the presence of DC in an inflammatory phenotype of 
chemical-induced asthma, we decided to change the airway exposure to an oropharyngeal instillation. 
In this mouse model, mice were dermally treated on dorsum of both ears followed by five oropharyngeal 
instillations within two weeks. 
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Abstract  
Both 2,4-toluene diisocyanate (TDI) and 4,4- methylene diphenyl diisocyanate (MDI) can cause 
occupational asthma. In this study, we optimized our mouse model of chemical-induced asthma in the 
C57Bl/6 mice strain using the model agent TDI. Furthermore, we validated MDI in this mouse model and 
investigated whether cross-reactivity between TDI and MDI is present. On days one and eight, C57Bl/6 
mice were dermally treated (20 μl/ear) with 3 % MDI, 2 % TDI or the vehicle acetone olive oil (AOO) 
(3:2). On day 15, they received a single oropharyngeal challenge with 0.04 % MDI, 0.01 % TDI or the 
vehicle AOO (4:1). One day later, airway hyperreactivity (AHR) and pulmonary inflammation in the 
broncho-alveolar lavage (BAL) were assessed. Furthermore, total serum IgE levels, lymphocyte 
subpopulations in auricular lymph nodes and cytokine levels in supernatants of lymphocytes were 
measured. Both dermal sensitization with TDI or MDI resulted in increased total serum IgE levels along 
with T and B cell proliferation in the auricular lymph nodes. The auricular lymphocytes showed an 
increased release of both Th2 and Th1 cytokines. Mice sensitized and challenged with either TDI or MDI 
showed AHR, along with a predominant neutrophil lung inflammation. Mice sensitized with MDI and 
challenged with TDI or the other way around showed no AHR, nor BAL inflammation. Both TDI and MDI 
are able to induce an asthma-like response in this mouse model. However, cross-reactivity between 
both diisocyanates remained absent. 
 
Keywords: 4,4′-Methylene diphenyl diisocyanate · 2,4-Toluene diisocyanate · Cross-reactivity · Occupational asthma · C57Bl/6 mice   
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Introduction 
Diisocyanates, low molecular weight agents containing two highly reactive isocyanate groups, are widely 
produced and consumed in industrialized countries 1. Predominantly, 4,4-methylene diphenyl 
diisocyanate (MDI) and 2,4-toluene diisocyanate (TDI) are used and account together for more than 90 
% of the global diisocyanate market. These chemicals are used for the production of polyurethanes, 
which are mainly present in products such as spray foam insulation, coatings, varnishes and paints 2. 
Nowadays, it is recognized that diisocyanates can cause occupational asthma (OA), which is the most 
common occupational respiratory disease in the industrialized world 3.  
The incidence of OA varies depending on the form and type of diisocyanate. Furthermore, it is 
influenced based on the level and duration of diisocyanate exposure 3. To date, it is well known that 
diisocyanates are potent sensitizers, with dermal exposure as the leading cause of sensitization. Once 
immune sensitization to diisocyanates occurs, low airborne levels [below the Occupational Safety and 
Health Administration (OSHA) established permissible exposure levels] can trigger asthmatic reactions 
4,5.  
Since evidence showed that TDI is an asthmogen, industry started working on ‘safer’ compounds. It is 
known that the basic structure of the monomer attached to the –NCO group (aliphatic or aromatic), and 
the number of –NCO groups alters the vapor pressure and reactivity of the monomer 3. The basic 
structure of TDI consists of one aromatic ring and is highly volatile at room temperature, while MDI is a 
solid and built upon 2 rings. Because of its lower vapor pressure and therefore safer use, MDI has 
become the most abundantly produced and consumed diisocyanate 6. Although MDI is safer than TDI, 
human and animal studies show that it also affects the respiratory system 5–10. 
The mechanism for diisocyanates to interact with the immune system is via protein binding, such as 
albumin 2,11,12. Binding to the ‘self’ protein albumin results into formation of immunogenic haptens 
which can trigger an immune response, associated with airway inflammation and asthma 6,12. At present, 
it is known that MDI and TDI react with 20 and 37 residues of albumin, respectively. All the residues of 
albumin to which MDI binds are analogous to those of TDI 2. 
Cross-reactivity is a phenomenon that occurs in daily practice, via cross-reactive IgEs of homologous 
proteins, e.g., between mushrooms and airborne molds, or between pollen (bee and weed) and 
different types of legumes (lupine and peanut) 13–15. Between chemicals cross-reactivity is also 
described. Patients sensitized to the chemical methylchloroisothiazolinone (MCI) can react to high levels 
of methylisothiazolinone (MI) and vice versa 16. Since the chemicals MDI and TDI have structural and 
binding similarities, it is important to study possible cross-reactivity between these diisocyanates. In the 
past, there was already immunological and respiratory evidence concerning cross-reactivity between 
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MDI and TDI, although the results remain contradictory and the number of patients included in the 
studies was limited 7,17–22. 
In light of the widely spread combinational use of both TDI and MDI, and to elucidate the contradictory 
results about cross-reactivity, we optimized our mouse model in the C57Bl/6 mice, tested whether MDI 
has the same potency as TDI to induce an asthmatic response and investigated possible cross-reactivity 
between TDI and MDI in our experimental mouse model of chemical-induced asthma. 
  
Cross-reactivity MDI and TDI 
42  
Materials and methods 
Reagents 
4,4′-Methylenebis phenyl diisocyanate (MDI) (89 %, CAS101-68-8), 2,4-toluene diisocyanate (TDI) (98 
%, CAS584-84-9), acetyl-β-methylcholine (methacholine) and acetone were obtained from Sigma-
Aldrich (Bornem, Belgium). Sodium chloride (NaCl) 0.9 % was obtained from B. Braun (Melsungen, 
Germany). Pentobarbital (Nembutal®) was obtained from Sanofi Santé Animale (CEVA, Brussel, Belgium) 
and isoflurane (Forene®) from Abbott Laboratories (Louvain-la-Neuve, Belgium). The vehicle acetone 
olive oil (AOO) used to dissolve MDI and TDI consists of a mixture of 2 volumes of acetone and 3 volumes 
of olive oil (selection de Almazara, Carbonell, Madrid, Spain) for the dermal sensitization and 1 volume 
of acetone and 4 volumes of olive oil for the challenge. Concentration of MDI is given as (w/v), while TDI 
is given as percentage (v/v) in AOO. 
Mice 
Male C57Bl/6 mice (6–8 weeks old) were obtained from Harlan (Horst, The Netherlands). All mice were 
housed under a conventional animal house with 12-h dark/light cycles. They were housed in filter-top 
cages and received lightly acidified water and pelleted food ad libitum. All experimental procedures 
performed in mice were approved by the local ethical committee for animal experiments (P118-2011). 
Experimental protocol  
 Illustration 1: acute exposure protocol. 
On days one and eight, mice received dermal applications of 20 μl of 3 % MDI, 2 % TDI or the vehicle 
AOO (2:3). On day 15, mice received, under light isoflurane anesthesia, an oropharyngeal instillation of 
20 μl 0.04 % MDI, 0.01 % TDI or the vehicle AOO (1:4). All experimental groups are indicated with 2 
symbols: The first symbol indicates the dermal treatment on days one and eight, whereas the second 
symbol indicates the oropharyngeal challenge on day 15. Each group consists of 7–10 mice. 
Airway and lung tissue hyperreactivity measurements 
Twenty-four hours after the challenge, airway and lung tissue reactivity to methacholine was measured 
using a forced oscillation technique (FlexiVent, SCIREQ, Montreal, Canada). Mice were anesthetized with 
pentobarbital (70 mg/ kg body weight, Nembutal®). Applying the ‘quick prime 3’ (QP3) perturbation, 
mice were exposed to increasing concentrations of methacholine (0, 1.25, 2.5, 5, 10, 20 mg/ml) 
dissolved in NaCl 0.9 % via an inline nebulizer to measure the airway resistance (Rn), tissue damping (G) 
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and tissue elasticity (H). After each concentration, the QP3 perturbation was performed 5 times spread 
over 2 min. If the coefficient of determination (COD) of a QP3 perturbation was lower than 0.90, the 
measurement was excluded and not used to calculate the average. For each mouse Rn, G and H were 
plotted against methacholine concentration and the area under the curve (AUC) was calculated to 
perform statistical analysis. 
Broncho-alveolar lavage (BAL) and serum sampling 
After measuring airway hyperreactivity to methacholine, mice were killed. Blood was sampled from the 
retro-orbital plexus and centrifuged (14,000g, 4 °C, 10 min), and serum samples were stored at −80 °C 
until analysis. The lungs were lavaged, in situ, three times with 0.7 ml sterile saline (0.9 % NaCl), and the 
recovered fluid was pooled. Cells were counted using a Bürker hemocytometer (total cell count), and 
the BAL fluid was centrifuged (1000g, 10 min). For differential cell counts, 250 μl of the resuspended 
cells (100,000 cells/ml) were spun (300 g, 6 min) (Cytospin 3, Shandon, TechGen, Zellik, Belgium) onto 
microscope slides, air-dried and stained (Diff-Quik® method, Medical Diagnostics, Düdingen, Germany). 
For each sample, 200 cells were counted for the number of macrophages, eosinophils and neutrophils. 
Lymph node analysis 
Retro-auricular lymph nodes, obtained from the same mice, were pooled and kept on ice in RPMI-1640 
(1×) + GlutaMAX™-I (Invitrogen, Merelbeke, Belgium). Cell suspensions were obtained by pressing the 
lymph nodes through a cell strainer (100 μm) (BD Bioscience, Erembodegem, Belgium) and rinsing with 
10 ml tissue culture medium (RPMI-1640 (1×) + GlutaMAX™-I). After centrifugation (1000g, 10 min), 
cells were counted using a Bürker hemocytometer and resuspended (107 cells/ml) in complete tissue 
culture medium (RPMI-1640 (1×) + GlutaMAX™-I supplemented with 10 % heatinactivated fetal bovine 
serum, 10 mg/ml streptomycin/penicillin). Five hundred thousand cells were stained with anti-CD3+ 
(APC), anti-CD4+ (APC-Cy7), anti-CD8+ (PerCP-Cy5.5) and anti-CD25+ (PE) or received a single staining 
with anti-CD19+ (PE)-labeled antibodies, according to standard procedures (BD Biosciences, 
Erembodegem, Belgium). Percentages of labeled cells were determined by performing flow cytometry 
(FACSArray, BD Biosciences, Erembodegem, Belgium) on at least 105 cells. Cells were seeded into 48-
well culture plates at a density of 106 cells/ml and incubated in complete RPMI-1640 (1X) + GlutaMAX™-
I for 42 h with 2.5 μg/ml of concanavalin A (ConA) (Sigma-Aldrich, Bornem, Belgium). Cell suspensions 
were then centrifuged (1000 g, 10 min), and supernatant was stored at −80 °C. Concentrations of 
interleukin-2 (IL-2), IL-4, IL-10, IL-13 and interferon gamma (IFN-γ) were measured via cytometric bead 
array and analyzed with the FCAPArray version 3 software (BD Biosciences, Erembodegem, Belgium) on 
the LSR Fortessa (BD Biosciences, Erembodegem, Belgium). Lower detection limits were, respectively, 
0.2, 0.3, 9.6, 2.4 and 0.5 pg/ml. 
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Total serum IgE 
The OptEIA Mouse IgE set from Pharmingen (BD Biosciences) was used to measure total serum IgE 
(diluted 1/70). Measurements were performed according to the manufacturer’s instructions. 
Data analyses 
The data are presented as means with standard error of the mean (SEM) or as individual mice and group 
means. Normality of distribution was assessed by the Kolmogorov–Smirnov test, followed by a one-way 
parametric ANOVA combined with a Bonferroni multiple comparison post hoc test (Graph Pad Prism 
5.01. Graphpad Software Inc, San Diego, USA). A level of p < 0.05 (two tailed) was considered to be 
significant. 
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Results 
Airway and lung tissue hyperreactivity 
Airway hyperreactivity (AHR), using a methacholine provocation test, was assessed 24 h after the 
challenge. Figure 1a, c, e shows the mean dose–response curves of airway and tissue hyperreactivity 
response to methacholine provocation, whereas fig. 1b, d, f shows the area under the curve (AUC) of 
the individual mice and the group average. Mice fully treated with MDI (MDI/MDI) or TDI (TDI/TDI) show 
a significant AHR, indicated by significantly increased Rn after methacholine challenge (fig. 1a, b), 
compared to the vehicle-treated control mice (AOO/AOO). The TDI/TDI group was also significantly 
increased compared to their control group AOO/TDI. Both cross-reactivity groups (TDI/MDI and 
MDI/TDI) show no AHR compared to all control groups (AOO/AOO, AOO/ MDI and AOO/TDI) (fig. 1a, b).  
A)        B)  
 
 
 
 
 
C) D)  
 
 
 
 
 
E) F)        
 
 
Fig. 1: Airway and tissue hyperreactivity. Airway and tissue hyperreactivity. Methacholine responsiveness was assessed 24 h after the oropharyngeal challenge. The airway (a, b) (Rn—airway resistance) and tissue reactivity (c–f) (G—tissue damping and H—tissue elasticity) to methacholine was measured using a forced oscillation technique. a, c, e Show mean values of Rn, G and H; b, d, f show individual values and the group mean of the area under the curve (AUC) of Rn, G and H against methacholineconcentrations between 0 and 20 mg/ml. Experimental groups are identified by two symbols, the first symbol indicates the dermal treatment on days 1 and 8, whereas the second symbol indicates the oropharyngeal challenge on day 15. n = 7–10 per group. *p < 0.05, **p < 0.01 compared to the AOO/AOO control group. #p < 0.05, ##p < 0.01 compared with the AOO/TDI control group. +p < 0.05 compared to the AOO/MDI group. 
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Regarding lung tissue hypersensitivity, there was a significantly increased tissue damping (G) compared 
to the vehicle-treated group. The TDI/TDI-treated group was also increased compared to their control 
group AOO/TDI. Furthermore, there was an increase in tissue elasticity (H) in both the TDI/TDI and 
MDI/MDI groups, compared to the full control group (AOO/AOO) and their own non-sensitized but 
challenged control group (AOO/TDI and AOO/MDI, respectively) (fig. 1c–f). 
Broncho-alveolar lavage 
Following AHR measurements, a broncho-alveolar lavage (BAL) was performed. Figure 2 shows the total 
number of macrophages, neutrophils and eosinophils in the BAL fluid. The total number of macrophages 
in the completely MDItreated mice is significantly lower compared to the vehicle- treated control group 
(AOO/AOO). The total number of neutrophils and eosinophils was significantly increased in completely 
TDI- and MDI-treated mice, compared to the vehicle-treated group (AOO/AOO) and their own non-
sensitized but challenged control group (AOO/TDI and AOO/MDI, respectively). In the cross-reactivity 
groups, only a limited inflammation was present, which was not significant. 
 
 
 
 
 
 
 
 
Fig. 2: Broncho-alveolar lavage (BAL) cell count. Total numbers of macrophages, neutrophils and eosinophils were assessed in BAL 24 h after the oropharyngeal challenge. Experimental groups are as in Fig. 1. n = 7–10 per group. Bars show the mean and SEM. *p < 0.05, **p < 0.01 compared to the AOO/AOO control group. #p < 0.05, ##p < 0.01 compared to the   AOO/TDI control group. +p < 0.05 compared to the AOO/MDI group. 
Auricular lymphocyte analysis 
The lymphocyte subpopulation of the auricular lymph nodes was assessed by FACSArray. Figure 3 shows 
the total number of CD3+ (T lymphocytes), CD3+CD4+ (Th lymphocytes), CD3+CD4+CD25+ 
(activated/regulatory Th lymphocytes), CD3+CD8+ (Tc lymphocytes) and CD19+ (B lymphocytes) cells in 
auricular lymph nodes. In the auricular lymph nodes of all mice sensitized with either TDI or MDI, there 
was a significantly increased number of both T and B lymphocytes, compared to the vehicle-treated 
group (AOO/AOO) and their own non-sensitized but challenged control group (AOO/TDI and AOO/MDI, 
respectively). The increase in T lymphocytes was due to a significant increase in all three subpopulations 
(Th lymphocytes, ctivated/regulatory Th lymphocytes and Tc lymphocytes).  
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Fig. 3: Lymphocyte subpopulations in auricular lymph nodes. Auricular lymphocytes were stained with anti-CD3+ (T lymphocytes), anti- CD3+CD4+ (Th lymphocytes), anti-CD3+CD4+CD25+ (activated/ regulatory Th lymphocytes) and anti-CD3+CD8+ (Tc lymphocytes) or stained with a single anti-CD19+ (B lymphocytes). Experimental groups are as in Fig. 1. n = 7–10 per group. Bars show the mean and SEM. **p < 0.01, ***p < 0.001 compared with the AOO/AOO control group. ##p < 0.01, ###p < 0.001 compared to the AOO/TDI control group. +p < 0.05, ++p < 0.01, +++p < 0.001 compared to the AOO/ MDI group. 
Auricular lymphocytes were cultured (42 h) with ConA (2.5 μg/ml). The levels of ex vivo release of IL-4 
(fig. 4a), IL-13 (fig. 4b) and IL-10 (fig. 4c) and IFN-γ (fig. 4d) in the supernatant are measured using 
cytometric bead array. Figure 4 shows that all mice sensitized with TDI or MDI have a significant increase 
in IL-4, IL-13, IL-10 and IFN- γ, compared to the vehicle-treated group (AOO/AOO) and their own non-
sensitized but challenged control group (AOO/TDI and AOO/MDI, respectively). 
A)          B)          C)  D) 
 
 
 
 
Fig. 4: Ex vivo cytokine production of auricular lymphocytes. Levels of IL-4 (a), IL-13 (b), IL-10 (c) and IFN-γ (d) were measured by cytometric bead array in supernatant of auricular lymphocytes. Experimental groups are as in Fig. 1. n = 7–10 per group. Bars show the mean and SEM. *p < 0.05, **p < 0.01, ***p < 0.001 compared to the AOO/AOO control group. #p < 0.05, ##p < 0.01, ###p < 0.001 compared to the AOO/TDI control group. +p < 0.05, ++p < 0.01, +++p < 0.001 compared to the AOO/MDI group.   
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Total serum IgE 
Total serum IgE was measured using standard ELISA assays. In fig. 5, the concentration of total serum 
IgE is presented. All mice sensitized to TDI and MDI show a significant increase in IgE, compared to the 
vehicle treated group (AOO/AOO) and their own non-sensitized but challenged control group (AOO/TDI 
and AOO/MDI, respectively). 
Fig. 5: Total serum immunoglobulin E. Blood was collected 24 h after the oropharyngeal challenge. Total serum IgE was measured using standard ELISA assays. Experimental groups are as in Fig. 1. n = 7–10 per group. Bars show the mean and SEM. ***p < 0.001 compared to the AOO/AOO control group. ###p < 0.001 compared to the AOO/TDI control group. +++p < 0.001 compared to the AOO/ MDI group.   
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Discussion 
4,4′-Methylene diphenyl diisocyanate (MDI) and toluene- 2,4-diisocyanate (TDI) are widely used 
chemicals in the polyurethane industry. Both diisocyanates are often used in the same plants, 
sometimes even together in the same production process 23. Since the structural and binding similarities 
and the contradictory result in humans concerning cross-reactivity, it is of importance to test possible 
cross-reactivity in our mouse model of chemical- induced asthma.  
Exposure to diisocyanates is associated with adverse health effects such as sensitization and asthma 24. 
Our results show that TDI is a potent asthmogen, which is in agreement with previous results obtained 
by our group and others 25–31. Furthermore, we demonstrated that MDI has the same asthmogenic 
potency as TDI in this mouse model of chemical-induced asthma. Yet, the most important novelty of 
this study is the fact that in both crossed groups either sensitized with TDI and challenged with MDI or 
sensitized with MDI and challenged with TDI, no airway/ tissue hyperreactivity or BAL inflammatory 
response could be found, thus showing no cross-reactivity. 
Previously, De Vooght et al. 32 showed that applying the same doses of TDI for sensitization and 
challenge, which give an asthma-like response in BALB/c mice, does not have the same result in the non-
atopic C57Bl/6 mice, which remained similar to the control treatment 32. Here, we demonstrated that 
by increasing the dermal sensitization concentration of TDI (0.3 % in BALB/c mice to 2 % in C57Bl/6 
mice), we are able to induce an asthma-like response in the C57Bl/6 mouse strain. An advantage is the 
wide availability of different KO C57Bl/6 mice strains for future mechanistic studies. Furthermore, 
C57Bl/6 mice may reflect asthma development in non-atopic persons.  
Based on the selected doses of MDI and TDI, we established dermal sensitization of the mice. This was 
demonstrated by the results of the different lymphocyte subpopulations, found in the auricular draining 
lymph nodes, which were significantly increased in mice sensitized to MDI or TDI. This was indicated by 
an increase in T helper (CD3+CD4+), T cytotoxic (CD3+CD8+), activated/ regulatory Th (CD3+CD4+CD25+) 
and B lymphocytes (CD19+). The cytokine release of ConA-stimulated lymphocytes displayed an 
increased mixed Th1/Th2 cytokine response, which is evidenced by an increased expression of Th2 
cytokines IL-13, IL-4, IL-10 as well as Th1 cytokine IFN-γ. This is in agreement with the previous findings 
26,29,33. The sensitization of the mice is also confirmed by an increase in total IgE after skin exposure of 
both MDI and TDI. This was also described by other groups for both chemicals 6,9,26,30. The role of IgE in 
diisocyanate-induced asthma is still under debate 34.  
Twenty-four hours after the single challenge, we observed that only mice receiving an antigen-specific 
oropharyngeal challenge with either TDI or MDI (TDI/TDI; MDI/MDI) resulted in lung inflammation 
characterized by mainly neutrophils and eosinophils, which is consistent with previous results using 
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BALB/c mice 33. The predominant neutrophilic inflammation is also observed in patients with TDI-
induced asthma and other TDI-induced animal models of asthma 26,30,31,35–37. For the first time, we 
confirm that also MDI induces an asthma-like response in this mouse model, indicated by an increase in 
eosinophils and mainly neutrophils in BAL fluid. Previously, other animal models showed increased 
levels of mainly neutrophils or eosinophils in BAL fluid after multiple exposures of MDI 6,9. This is in 
accordance with human studies, where MDI has been causally related to induce asthma, with symptoms 
such as variable airflow limitation, eosinophilic bronchitis and respiratory irritant effects after exposures 
on the work floor 10,38,39. 
Besides the lung inflammation, airway hyperreactivity (Rn) to increasing concentrations of methacholine 
(AHR) was measured 24 h later after the single challenge. Both TDI/TDI and MDI/MDI groups showed 
AHR compared to the complete control group. Furthermore, we also showed a significant increase in 
the TDI/TDI and MDI/MDI groups of tissue damping (G) and tissue elasticity (H), which is indicative for 
lung tissue hypersensitivity. This can be explained by the presence of epithelial necrosis and epithelial 
shedding after an oropharyngeal challenge as shown by De Vooght et al.33.  
Unlike the TDI/TDI and MDI/MDI group, the cross-reactivity groups (TDI/MDI and MDI/TDI) presented 
no asthma-like response. Despite successfully sensitized, no statistical changes in airway hyperreactivity 
and tissue hypersensitivity compared to the vehicle control group could be found. Furthermore, only a 
nonsignificant lung inflammation was present in the BAL. Yet, some mice in the cross-reactivity groups 
do show positive responses. This might be due to experimental variation, but it could also be due to 
actual cross-reactivity as shown for other chemicals 16. Human studies on cross-reactivity currently 
remain indecisive. Several research groups indicated that respiratory reactions can be elicited by other 
diisocyanates to which the workers were sensitized 8,21. Using inhalation provocation tests, O’Brien et 
al. demonstrated that four persons only exposed to TDI exhibited a bronchoconstrictive response to 
MDI inhalation 8. As already indicated, this was also seen in our results, and some mice in the cross-
reactivity groups (TDI/ MDI and MDI/TDI) showed AHR and neutrophils in BAL 24 h after the challenge. 
The crossed bronchial responses may be linked with crossed immunoreactivity. Immunological studies 
showed mutual cross-reactivity among isocyanate- bound human serum albumin (HSA) to which the 
workers were not sensitized 18–22,40. Also Ruwona et al. showed that murine monoclonal antibodies 
toward TDIHSA cross-react with MDI-HSA and HDI-HAS 41. Furthermore, Lemons et al. produced a 
murine IgM mAb with broad specificity toward the most commonly used isocyanates TDI-HSA, MDI-HSA 
and HDI-HSA 42. 
On the other hand, there is evidence in exposed workers that there is no crossed respiratory or 
immunological reaction to different types of diisocyanates, which is in line ith the main findings of this 
study 7,17,43. Mapp et al. demonstrated that in two patients sensitized to MDI, no drop of forced 
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expiratory volume in 1s (FEV1) was elicited after an inhalation challenge to TDI 7. The absence of 
respiratory cross-reactivity was also confirmed by immunological evidence. IgG antibodies to MDI, of 
subjects with asthma induced by MDI, appear to be specificor MDI without cross-reactivity with TDI 17. 
Furthermore, Wisnewski and Liu developed six different murine monoclonal antibodies which all bind 
to MDI-conjugated proteins, but not to TDI or HDI protein conjugates 12. 
The absence of cross-reactivity can be explained by the different reactivity of the functional group 
(diisocyanates) of MDI and TDI. Moreover, TDI has a higher affinity for lysine residues (e.g., on albumin), 
and therefore, MDI binds to less lysine residues compared to TDI 2,24. Also, the different stereo isomers 
of MDI and TDI may lead to a different binding to albumin, which makes it further difficult to generate 
the same epitope, although not exclusive. Theoretically, MDI and TDI have the ability to cross-react due 
to the communalities in albumin-binding sites. 
In this study, we established three major conclusions. First of all, we successfully optimized our mouse 
model of chemical-induced asthma in the C57Bl/6 mouse strain. Secondly, we conclude that MDI 
responses are similar to those of TDI in this model. Thirdly, the most important finding of this study is 
the absence of cross-reactivity between MDI and TDI. 
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Abstract 
Introduction: Exposure to diisocyanates is an important cause of occupational asthma (OA) in the 
industrialized world. Since OA occurs after long-term exposure to diisocyanates, we developed a chronic 
mouse model of chemical-induced asthma where TDI was administered at two different exposure sites.  
Aim: Study the presence of DC, T- and B- cells and effect of exposure route after long-term airway 
isocyanate exposure, with or without prior skin exposure. 
Method: On days 1 and 8, BALB/c mice were dermally treated (20µl/ear) with 0.5% TDI or the vehicle 
AOO (3:2). Starting from day 15, they received under light anesthesia five times in a week, for five 
successive weeks, intranasal instillations with 0.1% TDI or AOO (3:2). One day after the last instillation 
airway hyperreactivity (AHR) to methacholine was assessed, followed by an evaluation of pulmonary 
inflammation, structural lung changes and immune-related parameters such as lymphocyte 
subpopulations (CD4+, CD8+, CD25+ and CD19+) and in vitro cytokine production profile (IL-4, IL-13, IL-10 
and IFN-γ) in auricular and cervical lymph nodes. Blood was sampled to determine total serum IgE, IgG1, 
IgG2a and IL-13. Dendritic cells (DC), T- and B- cells were assessed in the lungs and ALN. 
Results: Our data indicate that mice repeatedly exposed via the nasal mucosa to TDI results in systemic 
sensitization, a mixed Th1/Th2 type immune response, without the presence of AHR. However, when 
mice are first sensitized with TDI via the skin, repeated nasal mucosa exposure to TDI leads to a 
pronounced Th2 response and AHR. 
Conclusion: Dermal exposure to TDI determines the respiratory outcome after repeatedly respiratory 
exposure to TDI. 
 
Keywords: Toluene diisocyanates, BALB/c mice, dendritic cells, paucigranulocytic asthma, IgE, airway 
hyperreactivity, Th2/Th1 response 
Chronic intranasal mouse model 
58  
Introduction 
Exposure to diisocyanates is an important cause of occupational asthma (OA). Diisocyanates are low 
molecular weight (LMW) compounds, used in spray foam insulation, plastic packaging and paints. They 
may act as haptens and bind with self-proteins to form functional antigens recognized by the immune 
system 1,2. To date, a growing body of animal and workplace observational studies suggest that skin 
exposure to isocyanates elicits immune sensitization. After sensitization, very low airway exposures, can 
elicit asthma 3–6. As a consequence, asthma still continues to occur even after reducing the airborne 
exposure below the occupational exposure limit (according to the American Conference of 
Governmental Industrial Hygienists 2015 the TLV is 0.001ppm) 4. 
Previously, we showed in a mouse model that dermal TDI sensitization can lead to asthma-like features 
after one TDI specific airway challenge, characterized by airway hyperreactivity (AHR), airway 
inflammation and Th1/Th2 immune response, which are mediated by the TRPA1 receptor, IL-13, B-
lymphocytes and neutrophils 7–13. However, despite the importance of unraveling the mechanistic 
pathways, the clinical relevance of such an acute asthma model is limited.  
Sub-chronic and chronic pulmonary exposure to diisocyanates has been studied before in rat and mouse 
to mimic human asthma 14–17. While T- and B- lymphocytes and the secreted cytokines have been 
investigated in diisocyanate asthma, little is known about the involvement of dendritic cells (DC) in this 
type of asthma 18. DC are the most important antigen presenting cells (APC) responsible for initiating an 
immune response. They are located near the epithelium, where they can sense and capture inhaled 
antigens present in the environment. After collecting, DC process the allergens into small peptides and 
migrate to the T cell zone of the local draining lymph nodes. There they present the processed antigens 
via the major histocompatibility complexes (MHC class I and II) to naive T cells, inducing polarized T cells 
19,20. In total, three distinct DC subsets are defined in the lung each with their own surface markers and 
functional specialization: conventional DC (cDC), which can be further divided in CD11b+ and CD103+ 
cDC, plasmacytoid DC (pDC) and monocyte derived DC (moDC) 21. Each of those DC subset are geared 
to induce a particular helper T cell respons. These responses are context dependent: environmental 
signals (house dust mite, cigarette smoke, diesel exhaust particles etc…), dose, routes of exposures and 
cell-released molecular patterns influence the function of DC which emphasize the plasticity of DC 21–24.  
We tested the importance of exposure route (dermal/respiratory) and the presence of DC, B- and T- 
cells in a chronic mouse model consisting of long-term nasal mucosa exposure, with or without a brief 
prior skin exposure. 
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Material and methods 
Reagents 
Toluene-2,4-diisocyanate (TDI) (98%, CAS584-84-9), acetyl-β-methylcholine (methacholine) and 
acetone were obtained from Sigma-Aldrich (Bornem, Belgium). Pentobarbital (Nembutal®) was 
obtained from the internal animalium at the KU Leuven. The vehicle acetone olive oil (AOO) used to 
dissolve TDI consists of a mixture of 2 volumes acetone and 3 volumes of olive oil (highly refined, low 
acidity, CAS8001-25-0) obtained from Sigma Aldrich. Concentration of TDI is given as percentage (v/v) 
in AOO.  
Mice 
Male BALB/c mice (6-8 weeks old) were obtained from the internal stock of the animalium (KU Leuven, 
Belgium). All mice were housed in a conventional animal house with 12h dark/light cycles, in filter top 
cages. They received lightly acidified water and pelleted food ad libitum. All experimental procedures 
were approved by the local Ethical Committee for animal experiments (P063/2015). 
Experimental protocol  
 Illustration 1: chronic exposure protocol. 
On days one and eight mice received dermal applications of 20 µl of 0.5% TDI or the vehicle AOO on the 
dorsum of both ears. From day 15, mice received, under light isoflurane anesthesia, intranasal 
instillations (20 µl) of 0.1% TDI or the vehicle AOO, 5 times a week for 5 consecutive weeks. All 
experimental groups are indicated with two symbols: the first symbol indicates the dermal treatment 
on days one and eight, whereas the second symbol indicates the intranasal instillations. The AOO/AOO 
group never received TDI, the AOO/TDI group only received intranasal TDI and the TDI/TDI group 
received TDI dermally and intranasally. Each group consisted of 6 to 17 mice. 
Analysis in different sets of experiments 
In this study, we have three different sets of experiments. In the first set, we evaluated the AHR, 
histological changes in the lung, IgE and IgG in blood serum, IgE and inflammation in BAL and T- and B- 
cells with in vitro cytokine secretion of the auricular and cervical lymph nodes (n=6-7/group). To increase 
the number of the auricular and cervical lymph nodes, we added a second set where we evaluated the 
T- and B- cells with in vitro cytokine secretion of the auricular and cervical lymph nodes (n=4-6/group). 
Endpoints
Days   1 8 15 22
Dermal sensitization Intranasalinstillation
29 36 43 50
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To analyze the DC, we added a third set. In the latter set we analyzed IgE in blood serum (to confirm 
sensitization), inflammation in BAL and DC, T- and B- cells in lung cells (n=8/group). In a subgroup of this 
set we also evaluated the T- and B- cells in the auricular and cervical lymph nodes (n=4/group). 
Airway and lung tissue hyperreactivity measurements 
Twenty-four hours after the last instillation, airway and lung tissue reactivity to methacholine was 
measured using a forced oscillation technique (FlexiVent 7.1, SCIREQ, Montreal, Canada). Mice were 
anesthetized with pentobarbital (70 mg/kg body weight, Nembutal®). Applying the ‘quick prime 3’(QP3) 
perturbation, airway resistance (Rn), and tissue elasticity (H) to increasing concentrations of 
methacholine (0, 1.25, 2.5, 5, 10, 20 mg/ml) was measured. After each concentration, the QP3 
perturbation was performed 5 times spread over 2 minutes. If the COD (Coefficient of Determination) 
of a QP3 perturbation was lower than 0.90, the measurement was excluded and not used to calculate 
the average. For each mouse Rn and H were plotted against methacholine concentration and the area 
under the curve (AUC) was calculated to perform statistical analysis.  
Lung, lymph node and serum analysis 
Serum sampling 
After measuring airway hyperreactivity to methacholine, mice were sacrificed. Blood was sampled from 
the retro-orbital plexus, centrifuged (14000 g, 4 °C, 10 min) and serum samples were stored at -80°C 
until analysis.  
Broncho-alveolar lavage (BAL) 
The lungs were lavaged, in situ, three times with 0.7 ml sterile saline (0.9% NaCl), and the recovered 
fluid was pooled. Cells were counted using a Bürker hemocytometer (total cell count) and the BAL fluid 
was centrifuged (1000 g, 10 min). For differential cell counts, 250 µl of the resuspended cells (100.000 
cells/ml) were spun (300 g, 6 min) (Cytospin 3, Shandon, TechGen, Zellik, Belgium) onto microscope 
slides, air-dried and stained (Diff-Quik® method, Medical Diagnostics, Düdingen, Germany). For each 
sample, 200 cells were counted for the number of macrophages, eosinophils, neutrophils and 
lymphocytes. 
Single cell suspension 
The pulmonary circulation was rinsed with saline/EDTA to remove the intravascular pool of cells. A cell 
suspension of the lungs was obtained using digestion medium (RPMI 1640 supplemented with 5% FCS, 
2 mM L-glutamine, 0.05 mM 2-mercaptoethanol [Gibco; Invitrogen, Paisley, United Kingdom], 100 U/mL 
penicillin–100 mg/mL streptomycin [Invitrogen], 1 mg/mL collagenase type 2 [Worthington 
Biochemical, Lakewood, NY], and 0.02 mg/mL DNase I [grade II from bovine pancreas; Boehringer 
Ingelheim, Ingelheim, Germany]) for 45 minutes at 37°C and 5% CO2. Red blood cells were lysed by 
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using ammonium chloride buffer. Cells were counted using a Bürker hemocytometer and resuspended 
(107 cells/ml) in PBS. 
The left and right retro-auricular as well as the two cervical lymph nodes from the same mice were 
pooled and kept on ice in RPMI-1640 (1X) + GlutaMAXTM-I (Invitrogen, Merelbeke, Belgium). Cell 
suspensions were obtained by pressing the lymph nodes through a cell strainer (100 μm) (BD Bioscience, 
Erembodegem, Belgium) and rinsing with 10 ml tissue culture medium (RPMI-1640 (1X) + GlutaMAXTM-
I). After centrifugation (1000 g, 10 min), cells were counted using a Bürker hemocytometer and 
resuspended (107 cells/ml) in complete tissue culture medium (RPMI-1640 (1X) + GlutaMAXTM-I 
supplemented with 10% heat-inactivated fetal bovine serum, 10 mg/ml streptomycin/penicillin).  
Flow cytometry 
T- and B- Cells 
Five-hundred thousand cells from the auricular/cervical lymph nodes and lung were stained with anti-
CD3+ (APC), anti-CD4+ (APC-Cy7), anti-CD8+ (PerCP-Cy5.5) and anti-CD25+ (PE), or received a single 
staining with anti-CD19+ (PE) labeled antibodies, according to standard procedures (BD Biosciences, 
Erembodegem, Belgium). Percentages of labeled cells were determined by performing flow cytometry 
(FACSArray, BD Biosciences, Erembodegem, Belgium) on at least 105 cells.  
 Dendritic cells 
To minimize non-specific bindings, two million cells of lung and auricular lymph nodes were 
preincubated with anti-CD16/CD32 (Clone 2.4G2 ) (from BD Biosciences, San Jose, Calif). After 
live/dead staining using the Zombie Aqua™ Fixable Viability Kit, cells were labeled with combinations 
of anti-mouse fluorochrome-conjugated mAbs against CD45 (clone 30-F11), CD11c (N418), MHCII 
(M5/114.15.2), CD11b (M1/70), CD103 (2E7), CD64 (X54-5/7.1) or Siglec-H (551) (all from Biolegend, 
San Diego, Calif). Data acquisition was performed on a LSR Fortessa flow cytometer running DIVA 
software (BD Biosciences, San Jose, Calif). FlowJo software (TreeStar, Inc, Ashland, Ore) was used for 
data analysis. We composed our DC panel based on those of sharen provoost et al. and Maud Plantinga 
et al. 21,24,25. 
Cytometric bead array 
Cells of the auricular and cervical lymph nodes were seeded into 48-well culture plates at a density of 
106 cells/ml and incubated in complete RPMI-1640 (1X) + GlutaMAXTM-I medium for 42h with 2.5 μg/ml 
of concanavalin A (ConA) (Sigma–Aldrich, Bornem, Belgium). Cell suspension were centrifuged (1000 g, 
10 min) and supernatant was stored at −80 °C. ConcentraƟons of interleukin (IL)-4, IL-10, IL-13 and 
interferon gamma (IFN-γ) were measured via the LSR Fortessa (BD Biosciences, Erembodegem, 
Belgium). Detection limits were 0.2 pg/ml, 0.3 pg/ml, 9.6 pg/ml, 2.4 pg/ml and 0.5 pg/ml, respectively. 
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Enzyme-linked Immunosorbent Assay (ELISA) 
The OptEIA Mouse IgE set from pharmingen (BD Biosciences) was used to measure total IgE in serum 
(diluted 1/70 for AOO/AOO and 1/1000 for the AOO/TDI and TDI/TDI treated group) and BAL (undiluted). 
Measurements were performed according to the manufacturer’s instructions. For the measurement of 
total serum IgG1 (diluted 1/8000 or 1/106) and IgG2a (diluted1/4000), plates were coated using purified 
rat anti-mouse IgG1 (Cat: 553445, BD PharmingenTM) and purified rat anti-mouse IgG2a (Cat: 553446, 
BD PharmingenTM). A standard was created using purified mouse IgG1 (Cat: 557273, BD PharmingenTM) 
and purified mouse IgG2a (Cat: 553454, BD PharmingenTM). Further measurements were performed 
according to the manufacturer's (BD Pharmingen) instructions with the use of biotinylated anti-mouse 
avidin horseradish peroxidase conjugate (HRP rat anti-mouse IgG1, Cat:559626, biotin rat anti-mouse 
IgG2a, Cat: 553388, and streptavidin HRP, Cat: 554066, BD PharmingenTM). 
Histology 
Lungs were instilled with 4% formaldehyde until full inflation of all lobes. An experienced pathologist 
evaluated lung injury on slides stained with hematoxylin and eosin (H&E), in a blinded manner. 
Data analyses 
The data are presented as means with standard deviation (SD), or as individual mice and group mean. 
Normality of distribution was assessed by the Kolmogorov-Smirnov test, followed by a one-way 
parametric ANOVA combined with a bonferroni multiple comparison post hoc test. Dose–response 
curves (AHR) were analysed using two-way parametric ANOVA, followed by a Bonferroni multiple 
comparison post hoc test (Graph Pad Prism 5.01. Graphpad Software Inc, San Diego, USA). A level of 
p<0.05 (two tailed) was considered significant. 
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Results 
Markers of sensitization 
Dendritic cells in auricular lymph nodes 
Figures 1B and C show a significant increase of DC, CD11b+ cDC in both groups receiving TDI (AOO/TDI 
and TDI/TDI) compared to the control group (AOO/AOO). Moreover, there is an increasing trend of 
moDC and a decreasing trend of CD103+ cDC and pDC in both TDI-treated groups (fig. 1C). Total amount 
of leukocytes were not significant increased (fig. 1A). 
 
Fig. 1: Leukocytes and dendritic cells ALN. Cells were analyzed using a flow cytometer. Leukocytes were assessed as CD45+ cells (a). DC were detected as low auto fluorescent MHCII+CD11c+ DC (b). Fig c demonstrates the parent % of CD45+ low auto fluorescent MHCII+CD11c+CD11b-CD103+ cDC (CD103+ cDC), CD45+ low auto fluorescent MHCII+CD11c+CD11b+CD103- conventional DC (CD11b+ cDC), CD45+ low auto fluorescent MHCII+CD11c+CD11b+ CD64+ monocyte derived DC (moDC), and CD45+ low auto fluorescent MHCII+ CD11c+ SiglecH+ plasmacytoid DC (pDC). Experimental groups are identified by two symbols; the first symbol indicates the dermal treatment on days 1 and 8, whereas the second symbol indicates the intranasal instillations. n=8 per group. Table shows the mean with SD. **p<0.01 and ***p<0.001 compared with the AOO/AOO control group.  
T- and B- cells in auricular and cervical lymph nodes  
Figure 2A shows that mice treated with TDI (AOO/TDI and TDI/TDI) have significantly more T-(CD3+) and 
B-(CD19+) cells in the auricular lymph nodes than the AOO/AOO control group. Moreover, all T cell 
subpopulations (CD4+ T helper, CD4+CD25+ activated/regulatory T cells and CD8+ cytotoxic T cells) were 
significantly increased in both TDI-treated groups. In the cervical lymph nodes (fig. 2B), in general lower 
numbers of T- and B- cells were found in the TDI-treated mice. CD19+ B cells were increased in both TDI 
treated groups, while CD8+ cytotoxic T cells were only increased in the AOO/TDI treated group (fig. 2B). 
Ex vivo cytokine secretion 
Ex vivo stimulation of auricular lymphocytes with concanavalin A resulted in significantly increased 
concentrations of IL-4, IL-13, IL-10 and IFN- in the TDI/TDI treated group (fig. 3A-D). While in the 
AOO/TDI treated group, a significant increase in IL-13 and IFN- was measured (fig. 3A-D). The ex vivo 
cytokine production of the cervical lymphocytes was substantially lower than in the auricular lymph 
nodes (fig 3E-H). In the TDI/TDI treated group, increased concentrations of IL-4, IL-13 and IL-10 were 
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found, while in the AOO/TDI treated group, only IL-13 was significantly increased (fig. 3E-G). The IFN- 
levels were not significantly changed (fig. 3H). 
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 Fig. 2: Lymphocyte subpopulations in auricular and cervical lymph nodes. Lymphocyte subpopulations in ALN (a) and CLN (b) were measured using flow cytometry. Lymphocytes were stained with anti-CD3+ (T lymphocytes), anti-CD3+CD4+ (Th-lymphocytes), anti-CD3+CD4+CD25+ (activated/regulatory Th-lymphocytes) and anti-CD3+CD8+ (Tc-lymphocytes) or stained with a single anti-CD19+ (B-lymphocytes). Experimental groups are as described in fig. 1. n= 14 per group. Bars show the mean with SD. *p<0.05, **p<0.01 and ***p<0.001 compared with the AOO/AOO control group. #p<0.05 compared to the AOO/TDI treated group.  
Fig. 3: Ex vivo cytokine production by auricular and cervical lymphocytes. Levels of IL-4 (a, e), IL-13 (b, f), IL-10 (c, g) and IFN-γ (d, h) were measured by Cytometric Bead Array in supernatant of auricular and cervical lymphocytes. Experimental groups are as described in fig. 1. n= 10-11 per group for the ALN, and 6-10 for the CLN. Bars show the mean and SD. *p<0.05, **p<0.01 and ***p<0.001 compared with the AOO/AOO control group. 
#p<0.05 and ###p<0.001 compared to AOO/TDI. 
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Immunoglobulines and serum IL-13  
Figure 4A shows that mice which received weekly intranasal instillations with TDI (AOO/TDI group), 
resulted in a significant increase of total serum IgE compared to the control (AOO/AOO) group. 
However, prior TDI skin sensitization, followed by TDI-intranasal instillations (TDI/TDI group) caused a 
much higher increase of IgE in serum, compared to the AOO-treated control group (fig. 4A). Besides the 
serum, IgE was also significantly increased in the BAL fluid of the TDI/TDI group (fig. 4D). IgG1 was 
significantly increased and IgG2a was significantly decreased in the serum of the TDI/TDI group compared 
to the control (AOO/AOO) group (fig. 4B and C). IL-13 in serum showed a step-wise significant increase 
in both TDI-treated groups (AOO/TDI and TDI/TDI), compared to the AOO control group. Nevertheless, 
the IL-13 levels in the TDI/TDI group was much higher compared to AOO/TDI group (fig. 4E).  
 
                          Fig. 4: Total levels of immunoglobulin (Ig) E, IgG1 and IgG2a and IL-13. Serum IgE (a), BAL IgE (d), serum IgG1 (b), serum IgG2a (c), and serum IL-13 (e) were measured using ELISA. Blood and BAL were collected 24h after the last intranasal challenge. Experimental groups are as described in fig. 1. n= 6-7 per group for serum IgG2a, IgG1, IL-13 and BAL IgE, and n=14-15 for serum IgE. Bars show the mean and SD. *p<0.05, **p<0.01 and ***p<0.001 compared with the AOO/AOO control group. 
##p<0.01 and ###p<0.001 compared to AOO/TDI. 
Airway response 
Airway hyperreactivity  
Figures 5A and C show the dose-response increase of methacholine-induced airway resistance and 
tissue elasticity, while figures 5B and D show the area under the curve of the individual mice and the 
group average. Airway hyperreactivity (AHR) in the TDI/TDI treated group were significant increased 
compared to both other groups (AOO/TDI and AOO/AOO).  
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Fig. 5: Airway and tissue hyperreactivity. Methacholine responsiveness was assessed 24h after the last intranasal challenge. The airway reactivity to methacholine was measured using a forced oscillation technique. Fig a and c show the mean values of Rn and H, respectively. Fig b and d show individual values and the group mean of the area under the curve (AUC) of Rn and H against methacholine concentrations between 0 and 20 mg/ml, respectively. Experimental groups are as described in fig. 1. n= 5-7 per group. *p<0.05, **p<0.01, ***p<0.001 compared with the AOO/AOO control group. #p<0.05 and ###p<0.001 compared to AOO/TDI treated group. 
Broncho-alveolar lavage and lung histology 
The AHR in the TDI/TDI treated group was not accompanied by an increase of inflammatory cells 
(neutrophils, eosinophils or lymphocytes) in the BAL fluid, where only macrophages were present (data 
not shown). Yet, histological analysis revealed that long-term intranasal exposure to TDI resulted in 
limited increased inflammation round the blood vessels , epithelial shedding and alveolar widening, 
although not significant (fig. 6A-C).  
T- and B- cells in the lung  
Table 1 shows a significant increase in CD3+D8+ cytotoxic T cells in the TDI/TDI treated group, compared 
to the AOO/AOO group. Yet, no statistical differences were found in CD3+ T helper cells of the TDI-
treated groups (AOO/TDI and TDI/TDI), compared to the AOO/AOO control group. 
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Fig. 6: Lung histology. H&E staining was performed on lung slices 24 after the last intranasal instillation. Alveolar widening (fig. 6a, 25x amplification), inflammation (fig. 6b, 200x amplification) and epithelial shedding (fig. 6c, 200x amplication) were validated. Experimental groups are as described in fig.1. n= 6-7 per group. Bars show the mean with SD.  
Table 1: Lymphocyte subpopulations in the lung. 
T cells lung (%) AOO/AOO AOO/TDI TDI/TDI 
CD3+ 9,09 ± 1,97 10,38 ± 1,76 10,77 ± 2,21 
CD3CD4+ 5,9 ± 1,38 6,76 ± 1,30 6,83 ± 0,98 
CD3CD4CD25+ 0,82 ± 0,37 1,12 ± 0,53 0,96 ± 0,22 
CD3CD8+ 2,63 ± 0,66 3,12 ± 0,62 3,50 ± 0,96* 
CD19+ 12,16 ± 3,59 9,69 ± 2,38 10,64 ± 3,42 
Lung cells were stained with anti-CD3+ (T lymphocytes), anti-CD3+CD4+ (Th lymphocytes), anti-CD3+CD4+CD25+ (activated/regulatory Th lymphocytes) and anti-CD3+CD8+ (Tc lymphocytes) or stained with a single anti-CD19+ (B lymphocytes). Experimental groups are as described in fig. 1. n= 12-14 per group. Bars show the mean with SD. *p<0.05 compared with the AOO/AOO control group.  
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Dendritic cells in the lung  
Figure 7D shows that only the moDC subpopulation in the lung from the TDI/TDI treated group is 
significantly increased compared to the AOO-treated control group. There were no significant changes 
in total number of leukocytes, dendritic cells, nor in the DC subpopulations: 103+cDC, CD11b+cDC, pDC 
and macrophages (fig. A-D).  
 
Fig. 7: Leukocytes, macrophages and DC subpopulations in the lung. Cells were analyzed using flow cytometry as CD45+ leukocytes (a), CD45+ low auto fluorescent MHCII+CD11c+ DC (DC) (c), CD45+ low auto fluorescent MHCII+CD11c+CD11b- CD103+ cDC (CD103+ cDC), CD45+ low auto fluorescent MHCII+CD11c+CD11b+ CD103- conventional DC (CD11b+ cDC), CD45+ low auto fluorescent MHCII+CD11c+CD11b+ CD64+ monocyte derived DC (moDC), and CD45+ low auto fluorescent MHCII+ CD11c+ SiglecH+ plasmacytoid DC (pDC) (d). Macrophages were analyzed as auto fluorescent cells (b). Experimental groups are as described in fig. 1. n=8 per group. Figure shows the mean with SD. *p<0.05 compared with the AOO/AOO control group. 
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Discussion 
To date, many efforts have been done to elucidate the underlying mechanisms of chemical-induced 
asthma. Yet, most of the work is performed in acute mouse models of chemical-induced asthma, with 
limited numbers of airway exposures 8,12,13,17,26–28. However, it takes weeks to years before initial onset 
of work related asthma symptoms occurs. As such, we aimed to investigate immunological parameters 
after long-term isocyanate exposure. Therefore, in contrast to our well-known acute mouse model 
consisting of dermal sensitization followed by one single airway exposure, we developed a chronic 
exposure model consisting of long-term airway exposures for five successive weeks, with or without 
prior brief skin exposure. Using this long-term model we were able to study both the effect of exposure 
sites (skin/respiratory) and the presence of immunological parameters such as dendritic cells, 
leukocytes, cytokines, T cells and immunoglobulins after long-term airway exposure. We showed in this 
study that TDI skin exposure in combination with repeated TDI airway exposure results in a pronounced 
Th2 hypersensitivity and AHR. Mice only exposed via the nasal mucosa to TDI, without prior dermal 
contact, showed a more Th1/Th2 balanced systemic response without the induction of airway 
hyperreactivity.  
As expected, the TDI/TDI treated group showed evidence of pronounced systemic sensitization. 
Interestingly, the AOO/TDI group showed also partly similar signs of systemic sensitization. It has already 
been described that TDI is able to migrate from the skin to the T cell rich area of the cortex in the dermal 
lymph nodes, where it is shown to be co localized with APC 29. This suggests that after TDI uptake, the 
APC migrate to the local lymph nodes and present TDI to the local T cells. Here we show that DC, T- and 
B- cells were significantly increased in both TDI treated groups. This was illustrated by a similar 
significant increase of cytotoxic T cells, regulatory T cells, helper T cells, B cells, CD11c+ and CD11b+ cDC, 
and an increasing trend of moDC in the ALN of both TDI-treated groups. As CD103+ and pDC both can 
induce T regulatory cells that damp allergic immune responses, the decrease of both cells confirms the 
sensitization to TDI 20. As we focused on the panel composition of DC in the lung, we are aware that we 
might have missed some dermal DC subpopulations in the TDI/TDI group 30.  
The sensitization is also proven by a significant increase of serum IgE in both groups. Yet, in the TDI-
dermally sensitized mice, the IgE serum concentration was three times higher than the AOO/TDI treated 
group. This suggests that contact of a sensitizer, with two different exposure sites, one skin and one 
airway mucosa, results in a much stronger immune response compared to only TDI airway exposure. 
Previously, Ban et al. and Matheson et al. showed similar results, where inhalation exposure resulted in 
a significant increase of total serum IgE 14,16.  
Another important immunological difference between AOO/TDI and TDI/TDI treated groups is 
illustrated by the cytokines. The AOO/TDI treated group showed a predominant Th1 response; indicated 
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by a very high increase of ex vivo IFN-γ secretion and increase of IL-13 concentration both in serum and 
ex vivo secretion. In contrast, the TDI/TDI treated group had a similar Th1 response, but a much more 
pronounced Th2 phenotype response, demonstrated by a very high ex vivo Th2 cytokine secretion (IL-
4, IL-10 and IL-13), along with high IL-13 serum levels. The pronounced Th2 response in the fully TDI-
treated group is also demonstrated by an increase of serum IgG1, along with IgE and decrease of IG2a in 
the serum. Again, this indicates that skin sensitization in combination with airway exposure leads to a 
pronounced Th2 response. Previously, Ban et al 2006 showed similar results when topical sensitization 
was followed by tracheal instillation, leading to a Th2 type lung inflammatory response, whereas 
sensitization via the airways was not effective 16.  
Yet, although both TDI treated groups (AOO/TDI and TDI/TDI) showed pronounced sensitization, only 
the TDI/TDI treated group showed AHR. Surprisingly, the AHR was not accompanied by a neutrophilic, 
nor an eosinophilic airway inflammation in BAL, and only very limited histological alteration in the blood 
vessels was found. An explanation could be that the delivered volume/dose of TDI into the lungs was 
too limited. To determine the volume of the intranasal instillation, we based ourselves on findings of 
Southam et al., who demonstrated that the instillation volume and anesthesia affect the distribution of 
substances in the lungs 31. Therefore, we performed the instillation under isoflurane anesthesia and 
increased the instillation volume to 40 µl. At this volume, 50-60% of the substance is distributed to the 
lungs 31. Yet, these distribution ranges are only demonstrated for substances dissolved in aqueous 
solutions. The use of the viscous vehicle acetone/olive oil will also limit the substance distribution and 
volume that reaches the lower airways 32.  
These results suggest that the Th2 immune response, induced by the combined skin and (upper) airway 
exposure, is necessary to induce AHR. Probably, as we showed previously in an acute mouse model of 
chemical-induced asthma, a complex interplay between neurogenic mechanisms (TRPA1 and NK1 
receptor), innate immune mechanisms (mast cells) and adaptive immune mechanisms are involved in 
the induction of airway hyperreacitivity 26. Notably, the IgE levels of the TDI/TDI treated group were 
three times higher compared to the AOO/TDI treated group, even five weeks after the initial dermal 
sensitization phase. Moreover, the levels of total serum IgE are 20 times higher than in our acute mouse 
model of chemical-induced asthma 8,26. The literature already showed a significant correlation between 
total serum IgE and the presence of asthma and AHR. As such, high levels of IgE can induce ongoing 
mast cell activation, which is crucial in our chemical-induced asthma mouse model 26,33–35. We measured 
the presence of IgE directly in the BAL fluid, which was significantly increased in TDI/TDI treated group. 
Furthermore, a key-role is attributed to IL-13 for inducing AHR. We also measured very high levels of 
the Th2 marker IL-13 in serum in the TDI/TDI treated group, confirming previously published research 
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36. The importance of initial topical exposure to chemicals on the airway response has been established 
for a while 6,8,11,16,26,37–40.  
An important novelty in our research is that we investigated whether dendritic cells, the most 
‘professional’ APCs in the lung and responsible for initiating an immune response and the induction of 
an asthmatic response, still play a role in the effector phase 46 days after the initial TDI contact 21,24,25. 
As this is still unstudied in isocyanate-induced asthma, we analyzed the different DC and T cell subsets 
in the lung 22,41. Although there was an increasing trend of some subpopulations in both AOO/TDI and 
TDI/TDI groups, there was no significant increase of DC in the lung after long-term exposures to TDI. 
This could be because DC, after allergen capture, migrate to the T cell area of the draining mediastinal 
lymph nodes (MLN) within twelve hours via a CCR7 dependent manner 41. Although there was no 
significant increase of DC, there was a shift between the DC subpopulations, illustrated by a significant 
increase of moDC. As they do not express CCR7, moDC do not migrate well to the draining nodes leading 
to an accumulation into the lung 42. moDC have the capacity to initiate and maintain a Th2 immune 
response which can explain the Th2 type sensitization in this chronic mouse model 21. The absence of 
DC in the lung after a long-term exposure protocol is in contrast with the findings of Provoost et al., 
Lambrecht et al. and Johnson et al. 21,24,25,43. The differences in response can be due to the different 
allergen exposure (house dust mite (Lambrecht et al. and Johnson et al.) and diesel exhaust particles 
(Provoost et al.)) and different airway exposure. Provoost et al. and Lambrecht et al. both used an 
intratracheal aspiration technique, which leads to a higher distribution to the lungs (80%) compared to 
the intranasal instillation method (50–60%) 21,24,31,44. Although Johnson et al. and lambrecht et al. used 
HDM as a potent allergen, both treatment protocols were different. Johnson et al. used a long-term 
treatment protocol in which mice were intranasally exposed 5 days/week for seven consecutive weeks 
with 25 µg HDM, while Lambrecht et al. used a short intratracheal instillation protocol in which mice 
were instilled once with 100 µg HDM. Although our treatment protocol is partly similar to Johnson et 
al., we were not able to detect an increase of DC in the lungs of mice treated with TDI. Therefore it is 
possible that the response in the lung is further influenced by the used vehicle:aqueous vehicle (saline 
or PBS), versus our much more viscous vehicle (Olive oil) which furthermore influence the distribution 
of the agent to the lungs32.  
Our findings indicate that repeated airway exposure to TDI causes immunological alterations indicative 
of sensitization, but are not accompanied by physiological changes indicative of asthma (i.e. AHR); 
however, the same type of exposure does lead to AHR if there has been previous dermal contact. These 
results implicate that long-term airway exposure to low TDI concentrations only results in asthma after 
previous accidental skin exposure, suggesting that dermal protection is important to protect TDI-
induced OA. 
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Abstract 
Introduction: Toluene diisocyanate (TDI) is a known lung irritant when exposure to high concentrations 
occurs, while exposure to low concentrations can lead to immune-mediated occupational asthma (OA). 
However, both lung responses are difficult to differentiate in the clinic. 
Aim: To determine differences between the immune-mediated and irritant TDI-induced lung response, 
we mimicked both phenotypes in a mouse model in which we assessed several lung parameters. 
Methods: On days one and eight, BALB/c mice were dermally treated (20µl/ear) with 0.5% TDI or the 
vehicle AOO (3:2). Starting from day 15, they received on days 15, 17, 19, 22 and 24 an oropharyngeal 
challenge with 0.01% TDI (1:4). One day after the last challenge, airway hyperreactivity (AHR) to 
methacholine was assessed, followed by an evaluation of pulmonary inflammation and immune-related 
parameters including lymphocyte subpopulations and their ex vivo cytokine production profile, blood 
immunoglobulins and dendritic cells (DC). 
Results: DC are recruited to inflamed lungs after multiple TDI airway exposure. However, prior dermal 
exposure determines the type of airway inflammation. Without prior skin exposure, the airway 
inflammation is dominated by mainly neutrophils, while prior skin exposure and consequently systemic 
immune sensitization, results in a shift from neutrophilic to eosinophilic airway inflammation 
accompanied with AHR.  
Conclusion: These results show that multiple airway exposures to low TDI concentrations are able to 
initiate an adaptive immune response indicated by an increased amount of DC in the lung. Additionally, 
Prior dermal exposure influences the inflammatory and physiological lung response. 
 
Keywords: Toluene diisocyanates, BALB/c mice, dendritic cells, Severe TDI-induced asthma  
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Introduction 
Asthma is a chronic inflammatory disorder of the airways with bronchial hyper-responsiveness to a 
variety of non-specific stimuli, persistent lung inflammation and variable airflow obstruction 1. In most 
of the cases, asthma begin in childhood, in association with IgE-dependent sensitization to common 
environmental allergens. Yet, asthma can also emerge later in life. This late onset asthma in older adults 
tends to be more severe than asthma that develops in younger age 2. 
Adult onset asthma is in 5 to 25% the result of exposure on the workplace, also defined ‘occupational 
asthma’ (OA) 3. OA can be classified in several sub phenotypes. High molecular weight (HMW) (such as 
flour, enzymes, latex, house dust mite,…) and some low molecular weight (LMW) agents (platinum salts, 
acid anhydrides,…) develop immune-mediated sensitization through the development of specific IgE, as 
similar seen in allergic asthma. On the other hand, some LMW compounds (diisocyanates and western 
red cedar) develop an immunologically mediated response in which IgE is not consistently seen 4,5. 
Moreover, the role of IgE in this phenotype of OA, is still under debate and the immune-mediated 
mechanisms are less well understood 6. The airway inflammation in both immunological phenotypes is 
postulated to be similar and characterized by mainly eosinophils 4. OA can also develop via a less well-
known non-immunological mechanism caused by exposure to high concentrations of irritant chemicals, 
called irritant-induced asthma. This phenotype of OA is recognized by a predominant neutrophilic 
airway inflammation 4,5. 
Toluene diisocyanates (TDI), a low molecular weight compound, are an important cause of chemical-
induced OA. High acute exposure to diisocyanates is known to cause irritant-induced asthma. Besides 
the acute toxicity/effects, diisocyanates are potent immune sensitizers resulting in immune-mediated 
asthma. Both asthma phenotypes are difficult to differentiate clinically 7. As diisocyanates are LMW 
compounds, they can act as haptens and bind to endogenous proteins before they are recognizable by 
the immune system. For a long time it was believed that airways were the key route of exposure in the 
development of TDI-induced asthma, however, to date, animal and human studies support the fact that 
skin exposure is an important route for sensitization. Once sensitized, low airborne concentrations can 
trigger an asthmatic response 8,9.  
Diisocyanate-induced asthma is often phenotyped by a severe neutrophilic airway inflammation and 
difficult to treat 10,11. Continuous exposure on the work floor results in worsening of symptoms such as 
airway obstruction and non-specific bronchial hyperresponsiveness. Therefore, the general therapeutic 
recommendation is to remove the workers from exposure to the causal agent 12. Yet, long-term follow 
up studies have shown that in 50% of TDI asthmatic patients taking anti-asthmatic medication, 
symptoms still are present even after cessation of exposure 13–17. Moreover, airway remodeling is shown 
to be decreased but airway inflammation and AHR persist to exist 16,17. In most of the studies, the 
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persistence of asthma is associated with the duration of exposure to TDI and the symptoms at work 
before diagnosis 15. The causal reason for the persistent asthmatic symptoms in some subjects remains 
unclear.  
Dendritic cells (DC) are important antigen presenting cells in the lung, bridging the innate and adaptive 
immunity. They have been shown to be crucial during both sensitization and effector phase of allergic 
asthma 18,19. However, the presence of DC in the lung tissue of diisocyanate-induced asthma has never 
been studied in an inflammatory phenotype.  
In this study, we investigated the differences in systemic (IgE, IgG and ex vivo cytokines) and lung 
response (airway hyperreactivity, DC, inflammation and histological changes) after multiple 
oropharyngeal instillations, with and without prior sensitization, which mimic immune-mediated 
asthma-like response and irritant-induced inflammation, respectively.  
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Material and methods 
Reagents 
Toluene-2,4-diisocyanate (TDI) (98%, CAS584-84-9), acetyl-β-methylcholine (methacholine) olive oil and 
acetone were obtained from Sigma-Aldrich (Bornem, Belgium). Pentobarbital (Nembutal®) was 
obtained from the internal animalium at the University of Leuven. The vehicle acetone olive oil (AOO) is 
used to dissolve TDI. For the sensitization phase, a mixture of 2 volumes acetone and 3 volumes of olive 
oil was used. For the challenge phase, a mixture of 1 volume actone and 4 volumes of olive oil was used. 
Concentration of TDI is given as percentage (v/v) in AOO.  
Mice 
Male BALB/c mice (6-8 weeks old) were obtained from the internal stock of the animalium (University 
of Leuven, Belgium). All mice were housed under a conventional animal house with 12h dark/light 
cycles. They were housed in filter top cages and received lightly acidified water and pelleted food ad 
libitum. All experimental procedures performed in mice were approved by the local Ethical Committee 
for animal experiments (P063/2015). 
Experimental protocol  
 
Illustration 1: sub-chronic exposure protocol 
On days one and eight, mice received dermal applications of 20 µl 0.5% TDI or the vehicle AOO (2:3) on 
the dorsum of both ears. On days 15, 17, 19, 22 and 24 mice received an oropharyngeal instillation with 
20 µl 0.01% TDI or the vehicle AOO (1/4). All experimental groups are indicated with two symbols: the 
first symbol indicates the dermal treatment on days one and eight, whereas the second symbol indicates 
the oropharyngeal instillations.  
In this study, we have two different sets of experiments. In the first set, we evaluated the AHR, lung 
histology and IgE, IgG, and IL-13 in blood serum. Furthermore we measured the cytokine secretion of T- 
and B- cells in the auricular lymph nodes (n=8-9/group). To study the DC in this mouse model, we added 
a second set were we performed a BAL to assess the lung inflammation, and studied the DC, T- and B- 
cells in the ALN and lung tissue. Furthermore, to confirm sensitization, we analyzed IgE in this set (n=8/ 
group). So depending on the endpoint, each group consisted of 6 to 17 mice. 
 
Endpoints
Days   1 8 15 22
Dermal sensitization Oropharyngealinstillation
29
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Airway and lung tissue hyperreactivity measurements 
Twenty-four hours after the last challenge, airway and lung tissue reactivity to methacholine was 
measured using a forced oscillation technique (flexiVent 6.3, SCIREQ, Montreal, Canada). Mice were 
anesthetized with pentobarbital (70 mg/kg body weight, Nembutal®). Using the ‘quick prime 3’ (QP3) 
perturbation, airway resistance (Rn) and tissue elasticity (H) to increasing concentrations of 
methacholine (0, 1.25, 2.5, 5, 10, 20 mg/ml) was measured. After each concentration, the QP3 
perturbation was performed 5 times spread over 2 minutes. If the COD (coefficient of determination) 
of a QP3 perturbation was lower than 0.90, the measurement was excluded and not used to calculate 
the average. For each mouse Rn and H were plotted against the methacholine concentration and the 
area under the curve (AUC) was calculated to perform statistical analysis.  
Lung, lymph node and serum analysis 
Serum sampling 
After measuring airway hyperreactivity, mice were sacrificed. Blood was sampled from the retro-orbital 
plexus, centrifuged (14000 g, 4 °C, 10 min) and serum samples were stored at -80°C until analysis.  
Broncho-alveolar lavage (BAL) 
The lungs were lavaged, in situ, three times with 0.7 ml sterile saline (0.9% NaCl), and the recovered 
fluid was pooled. Cells were counted using a Bürker hemocytometer (total cell count) and the BAL fluid 
was centrifuged (1000 g, 10 min). For differential cell counts, 250 µl of the resuspended cells (100,000 
cells/ml) were spun (300 g, 6 min) (Cytospin 3, Shandon, TechGen, Zellik, Belgium) onto microscope 
slides, air-dried and stained (Diff-Quik® method, Medical Diagnostics, Düdingen, Germany). For each 
sample, 200 cells were counted for the number of macrophages, eosinophils, neutrophils and 
lymphocytes. 
Single cell suspension 
Lung cells 
The pulmonary circulation was rinsed with saline/EDTA to remove the intravascular pool of cells. Cell 
suspension of the lungs were obtained using digestion medium (RPMI 1640 supplemented with 5% FCS, 
2 mM L-glutamine, 0.05 mM 2-mercaptoethanol [Gibco; Invitrogen, Paisley, United Kingdom], 100 U/mL 
penicillin–100 mg/mL streptomycin [Invitrogen], 1 mg/mL collagenase type 2 [Worthington 
Biochemical, Lakewood, NY], and 0.02 mg/mL DNase I [grade II from bovine pancreas; Boehringer 
Ingelheim, Ingelheim, Germany]) for 45 minutes at 37°C and 5% CO2. Red blood cells were lysed by 
using ammonium chloride buffer. Cells were counted using a Bürker hemocytometer and resuspended 
(107 cells/ml) in PBS. 
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Lymph node cells 
Retro-auricular lymph nodes were pooled and kept on ice in RPMI-1640 (1X) + GlutaMAXTM-I (Invitrogen, 
Merelbeke, Belgium). Cell suspensions were obtained by pressing the lymph nodes through a cell 
strainer (100 μm) (BD Bioscience, Erembodegem, Belgium) and rinsing with 10 ml tissue culture medium 
(RPMI-1640 (1X) + GlutaMAXTM-I). After centrifugation (1000 g, 10 min), cells were counted using a 
Bürker hemocytometer and resuspended (107 cells/ml) in complete tissue culture medium (RPMI-1640 
(1X) + GlutaMAXTM-I supplemented with 10% heat-inactivated fetal bovine serum, 10 mg/ml 
streptomycin/penicillin).  
Flow cytometry 
Lymphocyte subpopulations 
Five-hundred thousand cells from the auricular lymph nodes and lung were stained with anti-CD3+ 
(APC), anti-CD4+ (APC-Cy7), anti-CD8+ (PerCP-Cy5.5) and anti-CD25+ (PE), or received a single staining 
with anti-CD19+ (PE) labeled antibodies, according to standard procedures (BD Biosciences, 
Erembodegem, Belgium). Percentages of labeled cells were determined by performing flow cytometry 
(FACSArray, BD Biosciences, Erembodegem, Belgium) on at least 105 cells.  
 Dendritic cell subpopulations 
To minimize nonspecific bindings, two million cells of lung and auricular lymph nodes, were 
preincubated with anti-CD16/CD32 (Clone 2.4G2 ) (from BD Biosciences, San Jose, Calif). After 
live/dead staining using the Zombie Aqua™ Fixable Viability Kit, cells were labeled with combinations 
of anti-mouse fluorochrome-conjugated mAbs against CD45 (30-F11), CD11c (N418), MHCII 
(M5/114.15.2), CD11b (M1/70), CD103 (2E7), CD64 (X54-5/7.1) or Siglec-H (551) (all from Biolegend, 
San Diego, Calif). Data acquisition was performed on a LSR Fortessa flow cytometer running DIVA 
software (BD Biosciences, San Jose, Calif). FlowJo software (TreeStar, Inc, Ashland, Ore) was used for 
data analysis. 
Cytometric bead array 
Cells of the auricular lymph nodes were seeded into 48-well culture plates at a density of 106 cells/ml 
and incubated in complete RPMI-1640 (1X) + GlutaMAXTM-I medium for 42h with 2.5 μg/ml of 
concanavalin A (ConA) (Sigma–Aldrich, Bornem, Belgium). Cell suspension were centrifuged (1000 g, 10 
min) and supernatant was stored at −80 °C. Concentrations of interleukin (IL)-4, IL-10, IL-13 and 
interferon gamma (IFN-γ) were measured via the LSR Fortessa (BD Biosciences, Erembodegem, 
Belgium). Detection limits were 0.2 pg/ml, 0.3 pg/ml, 9.6 pg/ml, 2.4 pg/ml and 0.5 pg/ml, respectively. 
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Enzyme Linked Immuno Sorbent Assay (ELISA) 
The OptEIA Mouse IgE set from pharmingen (BD Biosciences) was used to measure total serum (diluted 
1/70) IgE. Measurements were performed according to the manufacturer’s instructions. For the 
measurement of total serum IgG1 (diluted 1/8000 or 1/20000) and IgG2a (diluted1/1000), plates were 
coated using purified rat anti-mouse IgG1 (Cat: 553445, BD PharmingenTM) and purified rat anti-mouse 
IgG2a (Cat: 553446, BD PharmingenTM). A standard was created using purified mouse IgG1 (Cat: 
557273, BD PharmingenTM) and purified mouse IgG2a (Cat: 553454, BD PharmingenTM). Further 
measurements were performed according to the manufacturer's (BD Pharmingen) instructions with the 
use of biotinylated anti-mouse avidin horseradish peroxidase conjugate (HRP rat anti-mouse IgG1, 
Cat:559626, biotin rat anti-mouse IgG2a, Cat: 553388, and Streptavidin HRP, Cat: 554066, BD 
PharmingenTM). 
Histology 
Lungs were instilled with 4% formaldehyde until full inflation of all lobes. An experienced pathologist 
evaluated lung injury on slides stained with hematoxylin and eosin (H&E), in a blinded manner. 
Data analyses 
The data are presented as means with standard error of the mean (SD), or as individual mice and group 
mean. Normality of distribution was assessed by the Kolmogorov-Smirnov test, followed by a one-way 
parametric ANOVA combined with a bonferroni multiple comparison post hoc test (Graph Pad Prism 
5.01. Graphpad Software Inc, San Diego, USA). A level of p<0.05 (two tailed) was considered to be 
significant. 
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Results 
Airway response 
Airway hyperreactivity  
Figures 1A and C show the dose-response increase of methacholine-induced airway resistance and 
tissue elasticity. Figures 1B and D show the area under the cure of each individual mice. Mice, sensitized 
and challenged with TDI (TDI/TDI treated group) showed a significant increase of airway hyperreactivity 
(AHR) and tissue elasticity compared to both AOO/AOO and AOO/TDI treated groups. 
 
Fig. 1: Airway and tissue hyperreactivity. Methacholine responsiveness was assessed 24h after the last oropharyngeal challenge. The airway reactivity to methacholine was measured using a forced oscillation technique. Fig a and c show the mean values of Rn and H, respectively. Fig b and d show individual values and the group mean of the area under the curve (AUC) of Rn and H against methacholine concentrations between 0 and 20 mg/ml. Experimental groups are identified by two symbols; the first symbol indicates the dermal treatment on days 1 and 8, whereas the second symbol indicates the oropharyngeal instillations. n=8-9 per group. **p<0.01, ***p<0.001 compared with the AOO/AOO control group. ##p<0.01 and ###p<0.001 compared with the AOO/TDI treated group. 
Broncho-alveolar lavage and lung histology 
Figure 2 shows the differential cell count of the BAL. Mice not sensitized and only exposed via the 
airways to TDI (AOO/TDI treated group) showed a significant increase of neutrophils compared to the 
AOO/AOO and TDI/TDI treated groups. Mice both sensitized and challenged with TDI (TDI/TDI) showed 
a highly significant influx of eosinophils in the BAL compared to both AOO/AOO and AOO/TDI treated 
groups. Macrophages were significant decreased in the AOO/TDI treated group compared to the 
AOO/AOO control group.  
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Fig. 2: Broncho-alveolar lavage (BAL) cell count. Percentages of macrophages, neutrophils, eosinophils and lymphocytes were assessed in BAL 24h after the last oropharyngeal instillation. Experimental groups are as in figure 1. n=8 per group. Bars show the mean and SD. *p<0.05, **p<0.01, ***p<0.01 compared to the AOO/AOO control group. #p<0.05 compared with the AOO/TDI treated group. ^^p<0.01 compared with the TDI/TDI treated group. 
 
 
These inflammatory results are confirmed by histological analysis, shown in figure 3 by an increase of 
alveolar widening (fig. 3A), inflammation (fig. 3B) and epithelial shedding (fig. 3C), in both TDI treated 
groups, nevertheless, the response was only significant in the fully treated TDI group (TDI/TDI) 
compared to both AOO/AOO and AOO/TDI treated groups (fig. 3A-C). 
 
Fig. 3: Histology of lung tissue. H&E staining was performed on lung slices 24h after the last oropharyngeal instillation. Alveolar widening (fig. 3a, 50x amplification), inflammation (fig. 3b, 200x amplification) and epithelial shedding (fig. 3c, 200x amplification) were validated. Experimental groups are as described in figure 1. n=7-9 per group. Bars show the mean with SD. **p<0.01 compared with the AOO/AOO control group. #p<0.05 compared with the AOO/TDI treated group.   
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Markers of sensitization 
Lymphocyte subpopulations in auricular lymph nodes  
Figure 4 shows that TDI-sensitized mice (TDI/TDI) have a significant increase of all T cell subpopulations 
(CD4+ helper T cells, CD4+CD25+ activated/regulatory T cells and CD8+ cytotoxic T cells) compared to the 
AOO/AOO and AOO/TDI treated groups. 
Fig. 4: Lymphocyte subpopulations in auricular lymph nodes. Lymphocyte subpopulations in auricular lymph nodes were measured using flow cytometry. Auricular lymphocytes were stained with anti-CD3+ (T lymphocytes), anti-CD3+CD4+ (Th-lymphocytes), anti-CD3+CD4+CD25+ (activated/regulatory Th-lymphocytes) and anti-CD3+CD8+ (Tc-lymphocytes) or stained with a single anti-CD19+ (B-lymphocytes). Experimental groups are as described in figure 1. n=8 per group. Bars show the mean with SD. **p<0.01, ***p<0.001 compared with the AOO/AOO control group. ##p<0.01, ###p<0.001 compared with the AOO/TDI treated group. 
Ex vivo cytokine secretion of the auricular lymph nodes 
Lymphocytes of the auricular lymph nodes were ex vivo stimulated with concanavalin A. Figure 5 shows 
a significant higher secretion of IL-4 (fig. 5A), IL-13 (fig. 5B), IL-10 (fig. 5C) and IFN- (fig. 5D) from the 
auricular lymphocytes of TDI/TDI treated mice compared to both AOO/AOO and AOO/TDI treated 
groups.  
 Fig. 5: Ex vivo cytokine production of auricular lymphocytes. Levels of IL-4 (a), IL-13 (b), IL-10 (c) and IFN-γ (d) were measured by Cytometric Bead Array in supernatant of auricular lymphocytes. Experimental groups are as described in figure 1. n=7-8 per group. Bars show the mean and SD. **p<0.01, ***p<0.001 compared with the AOO/AOO control group. ##p<0.01, ###p<0.001 compared with the AOO/TDI treated group. 
Dendritic cells in auricular lymph nodes 
As DC are important during the sensitization phase, we determined the number of DC in the auricular 
lymph nodes. Figures 6A to E show the total amount of leukocytes and different subpopulations of DC 
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in the ALN. There is no significant increase of total amount of leukocytes in the ALN in the TDI/TDI group 
compared to the control group AOO/AOO and AOO/TDI treated group (fig. 6A). Nevertheless, the 
dendritic cells (DC) (fig. 6B) and CD11b+ conventional dendritic cells (cDC) (fig. 6C) are significant 
increased in the TDI/TDI treated group compared to the control group (AOO/AOO) and AOO/TDI treated 
groups. CD103+cDC and pDC (fig. 6D and E) were only significant increased in the TDI/TDI group 
compared to the AOO/AOO treated group. 
Fig 6.: leukocytes and antigen presenting cells in auricular lymph nodes. Leukocytes and antigen presenting cells in auricular lymph nodes were measured using flow cytometry. Cells were analyzed as CD45+ low auto fluorescent MHCII+CD11c+ DC (DC) (b), CD45+ low auto fluorescent MHCII+CD11c+CD11b-CD103+ cDC (CD103+ cDC) (d), CD45+ low auto fluorescent MHCII+CD11c+CD11b+CD103- conventional DC (CD11b+ cDC) (c) and CD45+ low auto fluorescent MHCII+ CD11c+SiglecH+ plasmacytoid DC (pDC) (e). Experimental groups are as described in figure 1. n=8 per group. Figures show the individual values and group mean. *p<0.05, ***p<0.001 compared with the AOO/AOO control group. ##p<0.01, ###p<0.001 compared with the AOO/TDI treated group.  
Dendritic cells in the lung  
Figure 7 shows the total amount of leukocytes (fig. 7A), macrophages (fig. 7B), DC (fig 7C) and DC 
subpopulations (fig. 7D-G) in the lung. There is a significant increase of leukocytes in both groups treated 
with TDI (AOO/TDI and TDI/TDI) compared to the AOO/AOO control group (fig. 7A). The DC (fig. 7C), 
CD11b+ cDC (fig. 7D), CD103+cDC (fig. 7E) and moDC (fig. 7F) are also significantly increased in both TDI 
treated groups, compared to the AOO/AOO control group. Furthermore, pDC were increased in both 
TDI treated group, but was only significant in the AOO/TDI treated group (fig. 7G). Macrophages did not 
show significant differences (fig. 7B).  
Fig. 7: Leukocytes and antigen presenting cells in the lung. Leukocytes and antigen presenting cells in the lung were measured using flow cytometry. Cells were analyzed as CD45+ leukocytes (a), auto fluorescent macrophages (b) CD45+ low auto fluorescent MHCII+CD11c+ DC (DC) (c), CD45+ low auto fluorescent MHCII+CD11c+CD11b-CD103+ cDC (CD103+ cDC) (e), CD45+ low auto fluorescent MHCII+CD11c+CD11b+CD103- conventional DC (CD11b+ cDC) (d), CD45+ low auto fluorescent MHCII+CD11c+CD11b+CD64+ monocyte derived DC (moDC) (f) and CD45+ low auto fluorescent MHCII+CD11c+SiglecH+ plasmacytoid DC (pDC) (g). Experimental groups are as described in figure 1. n=8 per group. Figures show the individual values and group mean. Facs plots were shown using one representative mice (closed to the group mean) for each group. **p<0.01, ***p<0.01 compared with the AOO/AOO control group.  
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Serum analysis  
The serum analysis shows a significant increase in total serum IgE (fig. 8A) and IgG1 (fig. 8B) in TDI 
sensitized and challenged mice (TDI/TDI), compared to the AOO/AOO and AOO/TDI treated groups. 
There was no difference in total serum IgG2a and serum IL-13 between the different groups (data not 
shown). 
 
Fig. 8: Total serum immunoglobulins. Total serum IgE (a) and IgG1 (b) were measured using ELISA. Blood was collected 24h after the last oropharyngeal challenge. Experimental groups are as described in figure 1. n=15-17 for IgE and n=7-9 for IgG1 per group. Bars show the mean and SD. **p<0.01 and ***p<0.001 compared with the AOO/AOO control group. ##p<0.01, ###p<0.001 compared with the AOO/TDI treated group. 
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Discussion 
In this study, we show that inflammatory and physiological lung responses after multiple TDI airway 
exposures substantially differ between dermally sensitized and non-sensitized mice. In dermally 
sensitized mice, a more ‘classic’ Th2 mediated eosinophilic asthmatic response, with airway 
hyperreactivity appears, mimicking immune-mediated TDI-induced asthma, while in non-sensitized 
mice, a pronounced neutrophilic inflammation developed, without the presence of airway 
hyperreactivity, which is more reprehensive for irritant-induced inflammation. However, in both 
exposure protocols, DC are recruited to the lungs, indicating the early initiation of an adaptive immune 
response via lung exposure. 
Previously, we already described that dermal sensitization with TDI results in significantly proliferated 
auricular lymph nodes, where both T- and B- cells are stimulated. Here, we also show a significant 
increase of several DC subpopulations in the auricular lymph nodes. Dendritic cells are the most 
‘professional’ APCs for initiating an immune response. As the sensitization occurred on the dorsum of 
both ears, and studies have shown that diisocyanates are transported via DC from the skin to the local 
lymph nodes, we validated the presence of different DC subpopulations in the auricular lymph nodes 20. 
Depending on the exposure context, each DC subset is geared to induce particular T cell responses 21. 
Both CD11b+ and CD103+ cDC have shown to be able to induce a Th2 and Th1 immunization, respectively 
20. Their significant increase can therefore be directly linked to the increased number of CD4+ T cells in 
the ALN. CD103+DC are also described to cross present antigens to CD8+ T cells. Therefore, the 
significant increase of this type of DC can explain the significant increased numbers of CD8+ T cells in 
the ALN 20. Furthermore, the significant increase of CD103+ and pDC, can be responsible for the 
significant increase of CD25+ Tregs, which are known to diminish immune responses, and induce 
immune tolerance 22,23. Both humoral and ex vivo cell mediated cytokine secretion of the auricular lymph 
nodes demonstrated that there was a mixed Th2 (IgE, IgG1, IL-4, IL-10 and IL-13)/Th1 (IFN-γ) cytokine 
profile. The production of Th2 cytokines was probably initiated by moDC and CD11b+DC, as they are 
known Th2 immunity inducers. On the other hand, CD103+ and CD11b+cDC can be responsible for the 
Th1 response as they have been shown to induce a Th1 response ex vivo 22. 
Next to their role during the sensitization phase, DC also have a crucial role during the effector phase of 
asthma. In an OVA model, it is shown that depletion of CD11+DC during OVA airway exposures results 
in an abrogation of all the characteristic feature of asthma, however, these features were restored after 
adoptive transfer of CD11c+ cells 18,24. The role of DC in Th2 allergic mediated asthma phentoypes is 
crucial, however less is known about DC in a mixed Th1/Th2 asthmatic phenotype. Therefore, we 
assessed the DC recruitment in the airways of TDI treated mice, and studied the influence of prior 
dermal sensitization. 
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DC are recruited to the lungs of both TDI treated groups. Moreover, there is no difference in the DC 
subpopulations between both exposure groups. Also other studies confirmed recruitment of DC in the 
lung after diesel exhaust particles and HDM airway exposures 20,25–27. 
Our data indicate that dermal sensitization influences the inflammatory phenotype in the lungs. Both 
TDI-treated groups demonstrated a clear airway inflammation, however, depending on initial dermal 
TDI-sensitization the phenotype of inflammation was different. Mice only oropharyngeal instilled with 
TDI (AOO/TDI) have a predominant neutrophilic inflammation, rather reflecting an irritant, non-allergic, 
immune response, while mice both dermal sensitized and oropharyngeal instilled with TDI (TDI/TDI) 
illustrated a predominant eosinophilic inflammation reflecting a Th2 mediated allergic immune 
response. The increase of inflammatory cells are in line with the increase of moDC in both groups, which 
are known to rapidly appear in inflammatory sites 20.  
Surprisingly, despite a severe neutrophilic inflammation, AHR was only present in the fully treated 
TDI/TDI group. Besides differences in functional measurements and type of inflammation, there were 
also some significant structural changes in the lung such as an increased alveoli-widening, inflammation 
and epithelial shedding. These structural changes can be caused by the release of intracellular cytotoxic 
granules by the significant increased BAL eosinophils and the presence of the ex vivo IL-13 secretion 28.  
The absence of AHR and diminished histological changes in the AOO/TDI group can be explained by the 
absence of prior dermal sensitization and the high number of pDC in the lungs 22. We and other groups 
already emphasized the importance of previous skin exposure in inducing a pronounced airway 
response (26–28). The high number of pDC in the lung can be an explanation for the dampened lung 
response as they are able to induce immune tolerance via the induction of Tregs. 
As a conclusion, multiple airway exposure to TDI, with or without prior dermal sensitization, results in 
recruitment of DC, which are indicative of the early events of an adaptive immunity, accompanied with 
airway inflammation. Without prior skin exposure, this inflammation is dominated by mainly 
neutrophils, while prior skin exposure and consequently systemic immune sensitization results in a shift 
from a neutrophilic to an eosinophilic airway inflammation accompanied with AHR. These findings can 
have a direct implication for workers exposed on the work floor to diisocyanates. Depending on the skin 
protective clothing and gloves use during diisocyanate exposure, a different lung response develops 
when later exposure of diisocyanates to the lung occurs. Moreover, it is also important to notice, that 
low airborne concentration, without previous skin exposure, is able to initiate immune sensitization via 
the lungs which is illustrated by the increased DC in the lung.  
Sub-chronic oropharyngeal mouse model 
94  
Acknowledgments : This project was supported by a grant of the Interuniversity Attraction Poles 
Program-Belgian State-Belgian Science Policy- project P7/30, and by a grant of the Flemish Research 
Foundation (research grant 1504912N).  
Conflict of interest: The authors declare no conflict of interest. 
 Chapter 5 
95  
References 
1. Fajt, M. L. & Wenzel, S. E. Development of New Therapies for Severe Asthma. Allergy Asthma Immunol. Res. 9, 3–14 (2017). 
2. Holgate, S. T. et al. Asthma. Nat. Rev. Dis. Primer 1, 15025 (2015). 
3. Baur, X. et al. The management of work-related asthma guidelines: a broader perspective. Eur. Respir. Rev. Off. J. Eur. Respir. Soc. 21, 125–139 (2012). 
4. Wenzel, S. E. Asthma: defining of the persistent adult phenotypes. Lancet 368, 804–813 (2006). 
5. Dumas, O. & Le Moual, N. Do chronic workplace irritant exposures cause asthma? Curr. Opin. Allergy Clin. Immunol. 16, 75–85 (2016). 
6. Wisnewski, A. V. & Jones, M. Pro/Con debate: is occupational asthma induced by isocyanates an immunoglobulin E-mediated disease? Clin.Exp.Allergy 40, 1155–1162 (2010). 
7. Vandenplas, O. et al. EAACI position paper: irritant-induced asthma. Allergy 69, 1141–1153 (2014). 
8. Bello, D. et al. Skin exposure to isocyanates: reasons for concern. Environ. Health Perspect. 115, 328–335 (2007). 
9. Redlich, C. A. Skin exposure and asthma: is there a connection? Proc. Am. Thorac. Soc. 7, 134–137 (2010). 
10. Mapp, C. E., Butcher, B. T. & Fabbri, L. M. Polyisocyanates and their prepolymers. in Asthma in the workplace (eds. Bernstein, I. L., Chan-Yeung, M., Malo, J. L. & Bernstein, D. I.) 2, 457–478 (Marcel Dekker, Inc., 1999). 
11. Wenzel, S. E. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat.Med. 18, 716–725 (2012). 
12. Vandenplas, O. et al. Management of occupational asthma: cessation or reduction of exposure? A systematic review of available evidence. Eur. Respir. J. 38, 804–811 (2011). 
13. Park, H. S. & Nahm, D. H. Prognostic factors for toluene diisocyanate-induced occupational asthma after removal from exposure. Clin. Exp. Allergy J. Br. Soc. Allergy Clin. Immunol. 27, 1145–1150 (1997). 
14. Park, H.-S. et al. Metalloproteinase-9 is increased after toluene diisocyanate exposure in the induced sputum from patients with toluene diisocyanate-induced asthma. Clin. Exp. Allergy J. Br. Soc. Allergy Clin. Immunol. 33, 113–118 (2003). 
15. Pisati, G., Baruffini, A., Bernabeo, F., Cerri, S. & Mangili, A. Rechallenging subjects with occupational asthma due to toluene diisocyanate (TDI), after long-term removal from exposure. Int.Arch.Occup.Environ.Health 80, 298–305 (2007). 
16. Padoan, M. et al. Long-term follow-up of toluene diisocyanate-induced asthma. EurRespir J 21, 637–640 (2003). 
17. Saetta, M. et al. Airway wall remodeling after cessation of exposure to isocyanates in sensitized asthmatic subjects. Am. J. Respir. Crit. Care Med. 151, 489–494 (1995). 
18. van Rijt, L. S. et al. In vivo depletion of lung CD11c+ dendritic cells during allergen challenge abrogates the characteristic features of asthma. J.Exp.Med. 201, 981–991 (2005). 
Sub-chronic oropharyngeal mouse model 
96  
19. Lambrecht, B. N., Peleman, R. A., Bullock, G. R. & Pauwels, R. A. Sensitization to inhaled antigen by intratracheal instillation of dendritic cells. Clin.Exp.Allergy 30, 214–224 (2000). 
20. Plantinga, M. et al. Conventional and monocyte-derived CD11b(+) dendritic cells initiate and maintain T helper 2 cell-mediated immunity to house dust mite allergen. Immunity. 38, 322–335 (2013). 
21. Kopf, M., Schneider, C. & Nobs, S. P. The development and function of lung-resident macrophages and dendritic cells. Nat. Immunol. 16, 36–44 (2015). 
22. van Helden, M. J. & Lambrecht, B. N. Dendritic cells in asthma. Curr. Opin. Immunol. 25, 745–754 (2013). 
23. Lambrecht, B. N. & Hammad, H. Dendritic cell and epithelial cell interactions at the origin of murine asthma. Ann. Am. Thorac. Soc. 11 Suppl 5, S236-243 (2014). 
24. Lambrecht, B. N., Salomon, B., Klatzmann, D. & Pauwels, R. A. Dendritic cells are required for the development of chronic eosinophilic airway inflammation in response to inhaled antigen in sensitized mice. J Immunol 160, 4090–4097 (1998). 
25. Johnson, J. R. et al. Continuous exposure to house dust mite elicits chronic airway inflammation and structural remodeling. AmJRespirCrit Care Med 169, 378–385 (2004). 
26. Provoost, S. et al. Diesel exhaust particles stimulate adaptive immunity by acting on pulmonary dendritic cells. J.Immunol. 184, 426–432 (2010). 
27. Provoost, S., Maes, T., Joos, G. F. & Tournoy, K. G. Monocyte-derived dendritic cell recruitment and allergic T(H)2 responses after exposure to diesel particles are CCR2 dependent. JAllergy ClinImmunol 129, 483–491 (2012). 
28. Felton, J. M., Lucas, C. D., Rossi, A. G. & Dransfield, I. Eosinophils in the lung - modulating apoptosis and efferocytosis in airway inflammation. Front. Immunol. 5, 302 (2014). 
29. Wisnewski, A. V. et al. Immune sensitization to methylene diphenyl diisocyanate (MDI) resulting from skin exposure: albumin as a carrier protein connecting skin exposure to subsequent respiratory responses. J.Occup.Med.Toxicol. 6, 6 (2011). 
30. Ban, M. et al. TDI can induce respiratory allergy with Th2-dominated response in mice. Toxicology 218, 39–47 (2006). 
31. De Vooght, V. et al. Oropharyngeal aspiration: An alternative route for challenging in a mouse model of chemical-induced asthma. Toxicology 259, 84–89 (2009).
  
 
 
 
 
 
 
 
 
 
Chapter 6 
General discussion

 Chapter 6 
99  
1. Introduction 
Occupational asthma (OA) is a type of asthma caused by exposure to agents on the workplace. It has 
become one of the most common forms of occupational lung diseases in many industrialized countries 
and is responsible for 9-15% of adult asthma cases 1.  
Diisocyanates are important causes of chemical-induced OA. They are used in the polyurethane industry 
for the manufacture of flexible and rigid foams, fibers, paints and varnishes. Methylene diphenyl 
diisocyanate (MDI) and toluene diisocyanate (TDI), together account for more than 90% of the global 
diisocyanate market. Using their reactive isocyanate moiety (-N=C=O), they act as haptens reacting with 
alcohols, phenols, amines and thiols on endogenous proteins, forming functional antigens 2. 5 to 30% 
of the exposed workers are at risk to develop isocyanate-induced asthma 3. The general therapeutic 
recommendation is to remove the sensitized workers from exposure to the causal agent. Nevertheless, 
even after many years of cessation of exposure, more than 50% of TDI asthmatic patients taking anti-
asthmatic medication remain symptomatic 4,5. 
At present, the immunological mechanisms of the different phenotypes of chemical-induced OA are not 
fully elucidated. To study the underlying mechanisms, we developed several mouse models, mimicking 
different phenotypes of OA. Additionally, we validated MDI for its asthmatic potency and studied the 
cross-reactivity with TDI.  
2. Summary of the findings 
2.1  Evaluation of MDI and their cross-reactivity with TDI 
In a first study, we validated the asthmogenic potency of MDI and studied its cross-reactivity with TDI 
(chapter 3). Although MDI has a lower vapor pressure than TDI, and therefore is assumed safer in use, 
both human and animal studies show that exposure affects the respiratory system 6–11. Both 
diisocyanates are often used in the same plants and sometimes even together in the same production 
process. Moreover, they have common binding preference to lysine residues on human serum albumin 
(HSA), indicating that cross-reactivity might occur between both chemicals 2. In the past, several 
research groups focused on the immunological and respiratory cross-reactivity between MDI and TDI, 
yet the results remain contradictory and the number of patients included in the studies were limited 
7,12–17.  
Regarding the respiratory cases of MDI, their common binding places on HSA and contradictory results 
of cross-reactivity between MDI and TDI, we validated MDI for their asthmogenic potency and studied 
the asthmatic cross-reactivity with TDI in our acute mouse model of chemical-induced asthma. This 
General discussion 
100  
model consists of a dermal sensitization phase, induced via dermal applications on days one and eight, 
followed by a single oropharyngeal instillation on day 15 (fig. 6.1).   
 Fig. 6.1: Illustration of the acute exposure protocol. 
Our results demonstrated that mice sensitized and challenged with MDI resulted in a similar asthma-
like phenotype as previously shown with TDI, suggesting that both diisocyanates are potent asthmogens 
18–20. However, MDI seems to be a somewhat weaker sensitizer compared to TDI since we needed to 
increase the sensitization and challenge concentration of MDI to induce similar results 21. This acute 
mouse model is phenotyped by a predominant neutrophilic airway inflammation, airway hyperreactivity 
(AHR) and a mixed T helper (Th)1/Th2 response. Concerning cross-reactivity, we have found no or 
limited indications of cross-reactivity between TDI and MDI in this acute model.  
2.2  Developing phenotypes of chemical-induced asthma 
In the second part of this thesis, we aimed to develop different phenotypes of chemical-induced asthma. 
A gap in knowledge is the lack of a mouse model of chemical-induced asthma that shows robust lung 
inflammation and lung remodeling. Additionally, as dendritic cells (DC) are known to be important in 
both sensitization and elicitation phase of Th2-mediated ovalbumin (OVA)-induced asthma, we wanted 
to investigate the recruitment of DC in the lungs of a mixed Th1/Th2 phenotype of chemical-induced 
asthma 22.  
2.2.1 Chronic nasal mucosa exposure model 
In a first model, we aimed to develop a pronounced asthmatic response characterized by a pronounced 
AHR, airway inflammation and airway remodeling using TDI as model agent. Mice were dermally 
sensitized to TDI or vehicle treated on days one and eight followed by long-term nasal mucosa exposure, 
five days/week for five consecutive weeks (fig. 6.2), which is based on a mouse model of HDM-induced 
asthma that shows the anticipated outcome 23. To differentiate the influence of skin versus long-term 
airway exposure, we included three different groups in this study: mice only weekly exposed to TDI in 
the airways (AOO/TDI) and mice exposed to both skin and airways (TDI/TDI). Both groups were 
compared to the complete control group, receiving AOO both on the skin and in the airways (AOO/AOO) 
(chapter 4).  
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Fig. 6.2: Illustration of the chronic exposure protocol. 
Yet unexpectedly, airway inflammation and remodeling were absent in all groups. Only pronounced AHR 
was present in the TDI/TDI treated group, in fact mimicking the clinically relevant paucigranulocytic 
phenotype of chemical-induced asthma more than the anticipated Th2 inflammation-mediated asthma. 
Our data show that mice repeatedly exposed via the nasal mucosa to TDI (AOO/TDI group) results in 
systemic sensitization, indicated by a proliferation of the local lymph nodes (LN) (consisting of DC, T- 
and B- cells), increase of total serum IgE and ex vivo mixed Th1 (IFN-γ) /Th2 (IL-13) response of the LN 
cells, however, AHR is absent. Additional preceding TDI skin exposure (TDI/TDI group) results in a higher 
systemic sensitization, and a predominant Th2 response (high increase of ex vivo IL-13, IL-4, IL-10 and 
serum IL-13, IgE, IgG1 and decreased serum levels IgG2a) with the presence of AHR. DC were not migrated 
to the lungs in any of the groups.  
2.2.2 Sub-chronic oropharyngeal exposure model 
The absence of inflammation and airway remodeling using the intranasal challenge made us switch to 
the oropharyngeal challenge method as previously described by De Vooght et al. 18. By challenging 
deeper into the lung, we aimed to induce a pronounced inflammatory asthmatic response. Mice were 
dermally sensitized on days one and eight followed by five oropharyngeal challenges on days 15, 17, 19, 
22 and 24 (fig. 6.3). Similar as for the first chronic study, three exposure groups were included: one 
receiving five oropharyngeal instillations with TDI (AOO/TDI), and one additionally exposed to TDI via 
the skin (TDI/TDI). Both groups were compared to the complete control group, receiving AOO both on 
the skin and in the airways (AOO/AOO) (chapter 5). 
 
Fig. 6.3: Illustration of the sub-chronic exposure protocol. 
As a result both groups receiving multiple airway exposures to TDI, with (TDI/TDI) and without (AOO/TDI) 
prior dermal sensitization, showed an increasing recruitment of DC in the lung, which is indicative for 
the initiation of an adaptive immunity, accompanied with airway inflammation. Without prior skin 
Endpoints
Days   1 8 15 22
Dermal sensitization Intranasalinstillation
29 36 43 50
Endpoints
Days   1 8 15 22
Dermal sensitization Oropharyngealinstillation
29
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exposure, the inflammation in the lung is mainly dominated by neutrophils, while prior skin exposure 
and consequently systemic immune sensitization results in a shift from a neutrophilic to an eosinophilic 
airway inflammation accompanied with AHR. 
3. Relevance and limitations 
3.1  Cross-reactivity MDI and TDI 
MDI and TDI are both used in the polyurethane production and together account for more than 90% of 
the global diisocyanate market. As TDI and MDI are both used in the same plants and sometimes even 
together in the same production process, it is possible that employees can become dermally sensitized 
to MDI or TDI, and then exposed to low airborne concentrations of the other diisocyanate, which is an 
additional risk factor for the development of isocyanate-induced asthma. To date it is already well-
described in animal and human studies that both diisocyanates are potent asthmogens 7–10,24,25.  
3.1.1 MDI less potent than TDI 
Originally, our lab used BALB/c mice to validate chemicals and study the pathophysiology of chemical-
induced asthma in an acute mouse model (fig. 6.1). However, due to the lack of the wide availability of 
genetic modified BALB/c mouse strains and therefore limitations in mechanistic studies, the C57Bl/6 
mouse strain was introduced. Yet, De Vooght et al. reported that the TDI concentrations used in the 
BALB/c mouse, namely 0.3% for the dermal sensitization and 0.01% for the oropharyngeal challenge, 
do not result in an asthma-like response in the C57Bl/6 mouse strain 26. Therefore, we needed to adjust 
the TDI treatment concentrations in the C57Bl/6 mice to 2% for the dermal sensitization. The 
oropharyngeal challenge concentration remained the same (0.01%). To study the cross-reactivity 
between TDI and MDI, we additionally optimized the treatment concentrations for MDI in the acute 
C57Bl/6 mouse model of chemical-induced asthma. To induce similar asthma-like responses as TDI, we 
needed to increase the dermal sensitization and challenge concentration to 3% and 0.04% MDI, 
respectively. As a conclusion, both MDI and TDI are potent asthmogens, however TDI seems somewhat 
more potent than MDI. 
3.1.2 Cross-reactivity: yes or no? 
Cross-reactivity is a phenomenon that occurs in daily practice via cross-reactive IgE’s of homologue 
proteins such as mushrooms and airborne molds, pollen (bee and weed), different types of legumes 
(lupine and peanut) and between homologue chemicals such as methylchloroisothiazolinone (MCI) and 
methylisothiazolinone (MI) 27–30. As MDI and TDI have structural similarities and common binding places 
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on HSA we tested whether a crossed-asthmatic reaction exists between both diisocyanates. To our 
surprise, we could not show cross-reactivity between TDI and MDI in our acute mouse model.  
3.1.3 Concerns about cross-reactivity 
One could argue that there are signs of possible cross-reactivity in some mice. In both TDI/MDI and 
MDI/TDI treated groups, some mice show signs of AHR and lung inflammation, which might be 
attributable to cross-reactivity. Yet since the AOO/TDI and AOO/MDI control groups also show 
substantial variations in the lung parameters, we remain conservative in our conclusion.  
The lack of cross-reactivity can be explained by the fact that, due to their higher –N=C=O moiety 
reactivity towards endogenous proteins, TDI has a higher accessibility (34 lysine residues) on HSA than 
MDI (only 19 lysine residues) 2. Due to these many binding places on HSA and consequently large 
amount of possibilities for epitope formation, it is unlikely that TDI and MDI form the same epitopes. In 
addition, the different stereo isomers of MDI and TDI may lead to a different binding to albumin, which 
makes it further difficult to generate the same epitope. However, as all lysine binding places on HSA of 
MDI are the same as TDI, we cannot fully exclude similar epitope formation. It is possible that by 
increasing the number of airway exposures, as we did in chapter 5 (fig. 6.3), the chances of similar 
epitope formations increase and cross-reactivity may be present. Additional to the binding possibilities 
to HSA and different stereo isomers, epitope formation can be influenced by the predominant proteins 
present in different tissues. In studies investigating immunological cross-reactivity between 
diisocyanates, MDI and TDI were only used in conjugation with the same endogenous proteins 13,31,32. 
This is different to our study where we used ‘pure’ MDI or TDI to expose both skin and lung. Each tissue 
contains different predominant proteins potential, resulting in several different diisocyanate-protein 
conjugates in both tissues. Due to the potential high number of permutations, it is possible that, in the 
limited number of animals taken up in the cross-reactivity experiments, the epitopes formed during skin 
exposure differed simply by chance from the epitope formed during lung exposure. To overcome the 
drawback of the presence of different predominant proteins between tissues, we could have sensitize 
and challenge the mice with preformed TDI/MDI conjugates, using the same protein and reaction 
conditions.  
3.2 Phenotypes of chemical-induced asthma 
Since asthma is driven by genetic and environmental factors, it can result in different clinical outcomes, 
called phenotypes. Due to the complexity and heterogeneity of asthma, it is unlikely that one single 
mouse model can mimic all the features of asthma. By adjusting the treatment protocol, dosing and 
choice of mouse strains different phenotypes of asthma can be developed 33,34.  
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Several attempts to induce a severe chemical-induced inflammatory asthma phenotype have been 
described. Matheson et al. developed a chronic TDI mouse model in which C57BL/6 mice were exposed 
via the airways 5 times a week, for six consecutive weeks followed 2 weeks later by a single airway 
challenge 35. Lee et al. developed a model in which rats were intranasal treated with TDI for five 
consecutive days, followed by three inhalation exposures 36. Scheerens et al. sensitized BALB/c mice 
dermally via weekly exposures to TDI for six consecutive weeks followed by one intranasal challenge on 
week 7 37. Herrick et al. developed a hexamethylene diisocyanates (HDI) model in which BALB/c mice 
were dermally sensitized on days one and eight followed by four intranasal challenges within two weeks. 
Wisnewski et al. used the same treatment protocol to study the effect of MDI 25. Recently, Pauluhn et 
al. developed a TDI model in which Brown Norway and Wistar rats where dermally sensitized on days 
one and eight, followed by repeated (maximum four times) inhalation challenges varying from 10-60 
min.  
Although most groups showed lung inflammation, much less signs of airway remodeling including 
epithelial shedding, smooth muscle hyperplasia and collagen deposition were found compared to OVA 
and HDM mouse models of asthma 23,38,39. Therefore, we aimed to induce a severe phenotype of 
chemical-induced asthma with infiltration of inflammatory cells in the lung, AHR and airway remodeling.  
We developed a mouse model based on a chronic house dust mite model in which BALB/c were 
intranasally exposed to HDM for five days/week for seven consecutive weeks resulting in AHR, 
eosinophilic airway inflammation, DC recruitment in the lung and airway remodeling consisting out of 
goblet cell hyperplasia, collagen deposition and accumulation of contractile tissue 23. Since we know 
that dermal exposure is an important route of sensitization in TDI-induced asthma, we adapted the first 
two weeks of the HDM protocol to a dermal sensitization (fig. 6.2) 24. 
3.2.1 Challenge method determines phenotypical outcome 
In contrary to our hypothesis we found absolutely no signs of airway inflammation and airway 
remodeling after five weeks intranasal exposures to TDI. However, adding prior dermal sensitization 
resulted in AHR. One could argue, by using such long-term exposure mouse model, the absence of 
airway inflammation and airway remodeling could be due to the induction of tolerance. However, pilot 
studies demonstrated that even after two or three weeks of intranasal exposure, with or without dermal 
sensitization, airway inflammation is still absent (data not shown).  
The absence of airway inflammation and remodeling in this treatment regime is probably due to the 
combinational use of the intranasal instillation method and the viscous vehicle acetone olive oil in which 
TDI is dissolved. Southam et al. demonstrated that, using an intranasal challenge technique, the lung 
distribution of the compound is heavily influenced by the instilled volume and level of anesthesia. At 
least 30 to 35 µl of the test substance is necessary to reach the lower airways. Additionally, studies 
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demonstrated that aqueous vehicles (saline or PBS) flow more easily to the lower airways, while the 
viscous vehicle olive oil only seems to affects the nasal cavity 40,41. Yet, as diisocyanates are not stable in 
water and hydrolyze rapidly, it was required to use the viscous non-aqueous vehicle acetone olive oil.  
Considering these findings and compensate the drawback of the use of a viscous vehicle, we increased 
the intranasal instillation from 20 µl (volume in the acute mouse model) to 40 µl and sedated the animals 
during instillation 11,40,41. Yet, inflammatory lung response and airway remodeling remained absent, 
which is in contrast with the findings of Johnson et al.. Although similar treatment protocols are used, 
the different responses can be explained by the use of different allergens (house dust mite versus 
diisocyanates) and vehicles (saline versus olive oil) 23.  
As the intranasal instillation using viscous vehicles mainly targets the upper airways, we decided to use 
another mouse model to target the lower airways by bypassing the nose, using an oropharyngeal 
instillation technique described by De Vooght et al. 18. By bypassing the nose it has been shown to have 
a higher distribution to the lungs (80%) compared to the intranasal instillation method (50–60%) 40–44. 
Originally, for the intranasal instillation a concentration of 0.1% TDI was used, however, this 
concentrations caused too much mucosal irritation when given via oropharyngeal instillation. Therefore, 
the concentration was decreased to 0.01% TDI, which gave no signs of irritation. To perform this 
instillation, mice were anesthetized using isoflurane and held vertically. Next, TDI solution was pipetted 
at the end of the tongue. By grasping the tongue, and meanwhile closing the nose, the mice were 
prevented from swallowing. Although the oropharyngeal instillation technique is not invasive, the 
procedure is more intensive compared to the intranasal instillation. Oropharyngeal instillation targets 
more the lower airways and requires anesthesia. Consequently, it is not possible to execute the 
procedure on a daily basis. Therefore we decided to instill the mice every other day (3 times a week), 
for only two weeks long (fig. 6.3). Although the total dose was much less compared to the chronic nasal 
instillation protocol, the oropharyngeal instillation technique was suitable to induce a severe lung 
inflammation. Using a similar challenge technique, Provoost et al. and Plantinga et al. also founded 
inflammatory lung responses after exposure to diesel exhaust particles and HDM, respectively 42,43. 
3.2.2 Skin exposure determines phenotypical outcome 
During the last years, it has become clear that skin exposure is an important route of sensitization. Once 
sensitized via the skin, low airborne concentrations can elicit an asthmatic response 24. Moreover, both 
multiple exposure models (intranasal and oropharyngeal exposure) show that dermal exposure 
influence the phenotypical outcome in the lungs. 
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 Chronic nasal mucosa exposure model 
In this chronic model, we increased the sensitization concentration from 0.3% TDI (used in our acute 
BALB/c mouse model) to 0.5% to prolong the sensitization effects during the following intranasal 
challenges. Although nasal mucosa exposure to TDI results in systemic sensitization, shown by 
proliferated auricular lymph nodes, cytokine production profile and increased serum IgE titers, lung 
response remained absent. However, by dermally sensitizing mice with TDI prior to the intranasal 
exposures, AHR was present leading to a paucigranulocytic phenotype of asthma. The presence of AHR 
can be attributed to the systemically increase of Th2 mediators IgE (serum and BAL) and IL-13 (serum 
and ex vivo secretion). It is suggested that high levels IgE can induce ongoing mast cell activation, which 
consequently can result in a release of mediators such as IL-13. In parallel, mast cell can be activated by 
neurogenic mechanisms. Devos et al. demonstrated that, in a paucigranulocytic phenotype of asthma, 
TDI directly activates TRPA1 expressed on airway sensory nerves. This binding will lead to a release of 
neuropeptides such as substance P (SP). SP will consequently bind on its NK1 receptor expressed on the 
surface of mast cells, leading additionally to mast cell activation and a release of mediators such as IL-
13, a cytokine shown by our and other groups to be directly linked with AHR 38.  
One could argue that we have induced the same phenotype as already studied by Devos et al., however 
using this chronic exposure model we found some surprising interesting results. Depending on the site 
of exposure a different immune response developed. Nasal mucosa exposure resulted in a predominant 
Th1 response; indicated by a very high increase of ex vivo IFN-γ secretion and a low Th2 response 
indicated by the increase of IL-13 concentration both in serum and ex vivo secretion. Moreover, nasal 
mucosa exposure resulted in a significant increase of the auricular lymph nodes indicating that besides 
the ears the nose also drains these lymph nodes. However, adding dermal exposure, Th1 response is 
accompanied with a predominant Th2 response, demonstrated by a very high ex vivo Th2 cytokine 
secretion (IL-4, IL-10 and IL-13) and increase of serum IgE, IgG1 (a Th2 marker), IL-13 and decrease of 
IgG2a (a Th1 marker). This indicates that skin sensitization in combination with airway exposure leads to 
a pronounced Th2 response, which is also suggested by Ban et al., while nasal mucosa exposure results 
in a predominant Th1 response 45.  
The relevance of this study is, although airway inflammation and airway remodeling remained absent, 
that long-term low airborne TDI exposure leads to immune sensitization but do not results in an asthma-
like response. However, when the skin is exposed to TDI and sensitization occurs, TDI airway exposures 
finally lead to AHR. This emphasizes the importance of dermal protection when working with TDI on the 
work floor in order to prevent TDI-induced OA. 
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 Sub-chronic oropharyngeal exposure model 
The results of the chronic intranasal exposure model indicate that skin exposure influences the presence 
of AHR and type of immune response. Using our oropharyngeal instillation model, we additionally are 
able to investigate the influence of prior dermal exposure on the type of airway inflammation.  
Depending on the presence of dermal exposure, a different inflammatory phenotype developed. Mice 
only instilled with TDI in the airways developed a neutrophilic inflammation, which is indicative of an 
irritant inflammatory response, while by adding prior dermal exposure the same airway instillations 
results in a mainly eosinophilic airway inflammation accompanied with AHR, indicative for immune-
mediated inflammatory phenotype of asthma.  
3.2.3 Dendritic cells in chemical-induced asthma 
Dendritic cells (DC) are one of the most important antigen presenting cells (APC) responsible for 
initiating an immune response. They are located near the epithelium, where they can sense and capture 
inhaled antigens present in the environment. After phagocytosis, DC process the allergens into small 
peptides and migrate to the T cell zone of the local draining lymph nodes. There they present the 
processed antigens via the major histocompatibility complexes (MHC class I and II) to naive T cells, 
inducing polarized T cells 46,47.  
Distinct DC subsets are defined in the lung each with their own surface markers and functional 
specialization: conventional dendritic cells (cDC), which can be further divided in CD11b+ and CD103+ 
cDC, plasmacytoid DC (pDC) and monocyte derived DC (moDC) 42. Each of these DC subsets are equipped 
to induce particular T helper cell responses. These responses are context dependent: environmental 
signals (house dust mite, cigarette smoke, diesel exhaust particles etc…), dose, route of exposure and 
cell-released molecular patterns all influences the function of DC which emphasize the plasticity of DC 
42,43,48,49. DC are shown to be crucial during the sensitization and elicitation phase of Th2 mediated OVA 
induced asthma 22,50. Since the DC subtypes were not yet studied in chemical-induced asthma, we 
investigated the recruitment of DC in our chronic and sub-chronic mouse models of chemical-induced 
asthma. 
Long-term intranasal exposures, with or without previous skin sensitization, resulted in recruitment of 
DC in the local-auricular lymph nodes, which was accompanied by an increase of T- and B- cells. 
However, DC were not present in the lungs of the paucigranulocytic phenotype of asthma. As already 
explained in the previous paragraph, this can be due to intranasal challenge method. 
In the multi-oropharyngeal exposure protocol, DC were only present in the ALN after dermal 
sensitization. However, multi-oropharyngeal airway exposures resulted in airway inflammation 
accompanied with the recruitment of DC (CD11b+, moDC and pDC) in the lung. The recruitment of the 
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DC subpopulations is slightly different depending on the exposed compound (irritant versus allergen). 
Three days after one high exposure to the allergen HDM (not specified which der P extract is used), 
mainly moDC and lower amount (not significant) of CD11b+ were present in the lungs 42. While after 
three exposures to the irritant diesel exhaust particle, CD11b+, CD11b-cDC and moDC were increased in 
the lungs 43. In both models, pDC were not increased, which is a main difference with our results. These 
results confirm that the role of DC are context dependent (type of agent, exposure protocol, 
administered concentrations…). 
Although AHR and the type of inflammation depend on prior sensitization this is not the case for the DC 
recruitment to the lung. DC are recruited to the lungs of both irritant induced inflammation and immune 
mediated inflammatory phenotypes of asthma. The DC recruitment in the irritant-induced inflammatory 
phenotype indicates the potential initiation of an adaptive immune response in the lung. 
Taking the results of the DC in the chronic mouse model into account, DC only recruit to lung after 
inflammatory stimuli 23,43,51. 
3.2.4 Future perspectives 
Chronic nasal mucosa exposure model 
We need to take into account that by increasing the number of intranasal airway exposures the 
phenotypical outcome of both groups (AOO/TDI and TDI/TDI) can be changed. Therefore, an interesting 
next step would be to investigate if longer airway exposures (> five weeks) could lead to AHR without 
prior skin exposure. To answer this question, we need to increase the amount of intranasal challenges 
until the same levels IgE are reached as in the present TDI/TDI treated group. Another important aspect, 
which is not addressed in this thesis, is determining at which time point the dermal contact is crucial in 
the induction of TDI-induced asthma. Therefore, we can first perform a chronic airway exposure and 
subsequently expose them via the skin. Alternatively, we can first expose mice via the airways for a 
certain period, followed by skin exposure and subsequently expose them again via the airways. 
Moreover, it would be interesting to study the effect of simultaneous skin and airway exposure.  
 Sub-chronic oropharyngeal exposure model 
Although we were able to induce an inflammatory phenotype of asthma, airway remodeling was still 
absent. To study the underlying mechanisms of this asthma feature, we could increase the amount of 
multiple oropharyngeal instillations. 
The next step of this study would be the investigation of the contribution of DC in the induction of 
inflammation and AHR during the effector phase of chemical-induced asthma. This can be achieved by 
conditional deplete DC selectively during the airway exposures by adding diphtheria toxin (DT) in 
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transgenic (Tg) mice in which the CD11c promotor element drives the expression of the monkey DT 
receptor 51.  
After it has been shown that DC are crucial in the development of chemical-induced asthma, it would 
be of interest to study which chemokine ligand-chemokine receptor interaction is involved in the 
recruitment of DC to the lung during TDI exposure. For pulmonary tissue, there is no unique chemokine 
receptor that mediates DC recruitment and depending on the inflammatory stimulus, various 
chemokine ligand-chemokine receptor interactions appear to be implicated 52. In response to specific 
stimuli, lung epithelial cells produce chemokines that direct DC towards the mucosa upon binding to 
their chemokine receptors present on DC. For example, upon cigarette smoke it has been shown that 
CCR5 and CCR6, receptors for CCL5 and CCL20, respectively, seems to be crucial in DC lung recruitment. 
Provoost et al. demonstrated that, after exposure to diesel exhaust particles, moDC recruit to the lung 
in a CCR2-and to a less extent CCR6 dependent manner 52. As chemokine receptors are responsible for 
the recruitment of the DC to the lung, they are suggested to be a potent target for drugs development 
51. Therefore, it would be interesting to study the specific chemokine receptors involved in the 
recruitment of DC during TDI exposure. This could be achieved by using specific chemokine receptor 
knockout mice. Depending on the CCR involved in the DC recruitment after specific stimuli, different 
CCR blockers could be developed leading to personalized medicine. 
3.2.5 General limitations of both exposure models 
A first limitation of this study is the pulmonary dosing. We are aware that the inhalation exposure would 
mimic better the real life human exposure compared to the intranasal and oropharyngeal instillation 
techniques. However, inhalation exposure requires the use of specified equipment, it is technically 
demanding and time-consuming. Furthermore, it requires high amounts of chemicals, which could 
increase the risk of sensitization of the handler to the chemical.  
Another limitation of the chronic intranasal study is the fact that, although it is known in the literature 
that viscous solutions during an intranasal instillation mainly affects the nasal cavity, we did not studied 
the presence of inflammatory and dendritic cells in the nasal mucosa.  
The marker composition of the lung dendritic cell sub populations were based on the panel composition 
of both Provoost et al. and Plantinga et al. 42,43,52. However, in the discrimination between CD11b+ cDC 
and the moDC we did not used the marker CD64 in combination with MAR 1 (high-affinity IgE α chain 
receptor (FcεRIα)). MAR 1+ staining is used to compensate for the possible reduced CD64 staining 
intensity during migration of DC to the local lymph nodes. Therefore it is possible that we did not 
detected all moDC in the auricular lymph nodes 42.  
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The fourth limitation concerned the different markers of the dendritic cell subpopulations between the 
skin and lung. In this study, we focused on the panel composition of DC in the lung; yet, the same DC 
panel was used for the analysis of DC in the auricular lymph nodes that are probably migrated from the 
skin. Therefore, we are aware that we might have missed some dermal DC subpopulations in the 
auricular lymph nodes of TDI treated groups 42,43,48,56.  
4. Conclusion 
In this study, we found three main conclusions: 
 Both TDI and MDI are potent asthmogens, however, MDI is somewhat less potent as TDI. There is no 
cross-reactivity between both chemicals in an acute mouse model. 
 Skin exposure is necessary to induce AHR and determines the systemic immune response (Th1 versus 
Th2) and type of lung inflammation (eosinophilic versus neutrophilic).  
 DC only recruit to the lung after inflammatory stimuli.  
  
 Chapter 6 
111  
References 
1. Maestrelli, P., Boschetto, P., Fabbri, L. M. & Mapp, C. E. Mechanisms of occupational asthma. J. Allergy Clin. Immunol. 123, 531-542-544 (2009). 
2. Hettick, J. M. & Siegel, P. D. Comparative analysis of aromatic diisocyanate conjugation to human albumin utilizing multiplexed tandem mass spectrometry. IntJof Mass Spectrom. 309, 168–175 (2011). 
3. Hettick, J. M., Siegel, P. D., Green, B. J., Liu, J. & Wisnewski, A. V. Vapor conjugation of toluene diisocyanate to specific lysines of human albumin. Anal. Biochem. 421, 706–711 (2012). 
4. Padoan, M. et al. Long-term follow-up of toluene diisocyanate-induced asthma. EurRespir J 21, 637–640 (2003). 
5. Rüegger, M., Droste, D., Hofmann, M., Jost, M. & Miedinger, D. Diisocyanate-induced asthma in Switzerland: long-term course and patients’ self-assessment after a 12-year follow-up. J. Occup. Med. Toxicol. Lond. Engl. 9, 21 (2014). 
6. Woods, G. Making polyurethanes. in The ICI polyurethanes book Second edition, 10–12 (John Wiley & Sons, 1990). 
7. Mapp, C. E., Dal, V. L., Boschetto, P. & Fabbri, L. M. Combined asthma and alveolitis due to diphenylmethane diisocyanate (MDI) with demonstration of no crossed respiratory reactivity to toluene diisocyanate (TDI). Ann.Allergy 54, 424–429 (1985). 
8. O’Brien, I. M., Harries, M. G., Burge, P. S. & Pepys, J. Toluene di-isocyanate-induced asthma. I. Reactions to TDI, MDI, HDI and histamine. Clin.Allergy 9, 1–6 (1979). 
9. Pauluhn, J. Brown Norway rat asthma model of diphenylmethane 4,4’-diisocyanate. Inhal.Toxicol. 17, 729–739 (2005). 
10. Tanser, A. R., Bourke, M. P. & Blandford, A. G. Isocyanate asthma: respiratory symptoms caused by diphenyl-methane di-isocyanate. Thorax 28, 596–600 (1973). 
11. Vanoirbeek, J. ., Tarkowski, M., Hoet, P. M. H., Ceuppens, J. L. & Nemery, B. Development of a Murine Model of Chemical-Induced Asthma. Ventilatory and Lung Inflammatory Changes in Mice Dermally Sensitized to Toluene Diisocyanate. AmJRespirCrit Care Med (2004). 
12. Aul, D. J. et al. Specific IgG response to monomeric and polymeric diphenylmethane diisocyanate conjugates in subjects with respiratory reactions to isocyanates. JAllergy ClinImmunol 103, 749–755 (1999). 
13. Baur, X. Immunologic cross-reactivity between different albumin-bound isocyanates. JAllergy ClinImmunol 71, 197–205 (1983). 
14. Grammer, L. C., Harris, K. E., Malo, J. L., Cartier, A. & Patterson, R. The use of an immunoassay index for antibodies against isocyanate human protein conjugates and application to human isocyanate disease. JAllergy ClinImmunol 86, 94–98 (1990). 
15. Lushniak, B. D., Reh, C. M., Bernstein, D. I. & Gallagher, J. S. Indirect assessment of 4,4’-diphenylmethane diisocyanate (MDI) exposure by evaluation of specific humoral immune responses to MDI conjugated to human serum albumin. Am.J.Ind.Med. 33, 471–477 (1998). 
General discussion 
112  
16. Malo, J. L., Ouimet, G., Cartier, A., Levitz, D. & Zeiss, C. R. Combined alveolitis and asthma due to hexamethylene diisocyanate (HDI), with demonstration of crossed respiratory and immunologic reactivities to diphenylmethane diisocyanate (MDI). JAllergy ClinImmunol 72, 413–419 (1983). 
17. Wass, U. & Belin, L. Immunologic specificity of isocyanate-induced IgE antibodies in serum from 10 sensitized workers. JAllergy ClinImmunol 83, 126–135 (1989). 
18. De Vooght, V. et al. Oropharyngeal aspiration: An alternative route for challenging in a mouse model of chemical-induced asthma. Toxicology 259, 84–89 (2009). 
19. De Vooght, V. et al. B-lymphocytes as key players in chemical-induced asthma. PloS One 8, e83228 (2013). 
20. De, V., V. et al. Neutrophil and eosinophil granulocytes as key players in a mouse model of chemical-induced asthma. Toxicol.Sci. 131, 406–418 (2013). 
21. Selgrade, M. et al. Inconsistencies between cytokine profiles, antibody responses, and respiratory hyperresponsiveness following dermal exposure to isocyanates. Toxicol.Sci. 94, 108–117 (2006). 
22. van Rijt, L. S. et al. In vivo depletion of lung CD11c+ dendritic cells during allergen challenge abrogates the characteristic features of asthma. J.Exp.Med. 201, 981–991 (2005). 
23. Johnson, J. R. et al. Continuous exposure to house dust mite elicits chronic airway inflammation and structural remodeling. AmJRespirCrit Care Med 169, 378–385 (2004). 
24. Redlich, C. A. Skin exposure and asthma: is there a connection? Proc. Am. Thorac. Soc. 7, 134–137 (2010). 
25. Wisnewski, A. V. et al. Immune sensitization to methylene diphenyl diisocyanate (MDI) resulting from skin exposure: albumin as a carrier protein connecting skin exposure to subsequent respiratory responses. J.Occup.Med.Toxicol. 6, 6 (2011). 
26. De Vooght, V. et al. Choice of mouse strain influences the outcome in a mouse model of chemical-induced asthma. PLoS.One. 5, e12581 (2010). 
27. Choi, J. H., Jang, Y. S., Oh, J. W., Kim, C. H. & Hyun, I. G. Bee Pollen-Induced Anaphylaxis: A Case Report and Literature Review. Allergy Asthma ImmunolRes (2014). 
28. Gabriel, M. F. et al. From respiratory sensitization to food allergy: Anaphylactic reaction after ingestion of mushrooms (Agaricus bisporus). Med.Mycol.Case.Rep. 8, 14–16 (2015). 
29. van, K., V. et al. IgE Sensitization to Lupine in Bakers - Cross-Reactivity or Co-Sensitization to Wheat Flour? IntArchAllergy Immunol 166, 63–70 (2015). 
30. Lundov, M. D., Krongaard, T., Menne, T. L. & Johansen, J. D. Methylisothiazolinone contact allergy: a review. Br.J.Dermatol. 165, 1178–1182 (2011). 
31. Wisnewski, A. V. & Liu, J. Molecular determinants of humoral immune specificity for the occupational allergen, methylene diphenyl diisocyanate. Mol.Immunol. 54, 233–237 (2013). 
32. Lemons, A. R. et al. A murine monoclonal antibody with broad specificity for occupationally relevant diisocyanates. J.Occup.Environ.Hyg. 11, 101–110 (2014). 
33. Nials, A. T. & Uddin, S. Mouse models of allergic asthma: acute and chronic allergen challenge. Dis.Model.Mech. 1, 213–220 (2008). 
 Chapter 6 
113  
34. Chapman, D. G., Tully, J. E., Nolin, J. D., Janssen-Heininger, Y. M. & Irvin, C. G. Animal models of allergic airways disease: where are we and where to next? J. Cell. Biochem. 115, 2055–2064 (2014). 
35. Matheson, J. M., Johnson, V. J., Vallyathan, V. & Luster, M. I. Exposure and immunological determinants in a murine model for toluene diisocyanate (TDI) asthma. Toxicol. Sci. Off. J. Soc. Toxicol. 84, 88–98 (2005). 
36. Lee, S.-H. et al. Mesenchymal stem cell transfer suppresses airway remodeling in a toluene diisocyanate-induced murine asthma model. Allergy Asthma Immunol. Res. 3, 205–211 (2011). 
37. Scheerens, H. et al. Long-term topical exposure to toluene diisocyanate in mice leads to antibody production and in vivo airway hyperresponsiveness three hours after intranasal challenge. AmJRespirCrit Care Med 159, 1074–1080 (1999). 
38. Hacha, J. et al. Nebulized anti-IL-13 monoclonal antibody Fab’ fragment reduces allergen-induced asthma. Am. J. Respir. Cell Mol. Biol. 47, 709–717 (2012). 
39. Van Hove, C. L. et al. Comparison of acute inflammatory and chronic structural asthma-like responses between C57BL/6 and BALB/c mice. IntArchAllergy Immunol 149, 195–207 (2009). 
40. Ebino, K., Lemus, R. & Karol, M. H. The importance of the diluent for airway transport of toluene diisocyanate following intranasal dosing of mice. Inhal.Toxicol. 11, 171–185 (1999). 
41. Southam, D. S., Dolovich, M., O’Byrne, P. M. & Inman, M. D. Distribution of intranasal instillations in mice: effects of volume, time, body position, and anesthesia. AmJPhysiol Lung Cell MolPhysiol 282, L833–L839 (2002). 
42. Plantinga, M. et al. Conventional and monocyte-derived CD11b(+) dendritic cells initiate and maintain T helper 2 cell-mediated immunity to house dust mite allergen. Immunity. 38, 322–335 (2013). 
43. Provoost, S. et al. Diesel exhaust particles stimulate adaptive immunity by acting on pulmonary dendritic cells. J.Immunol. 184, 426–432 (2010). 
44. Foster, W. M., Walters, D. M., Longphre, M., Macri, K. & Miller, L. M. Methodology for the measurement of mucociliary function in the mouse by scintigraphy. J.Appl.Physiol 90, 1111–1117 (2001). 
45. Ban, M. et al. TDI can induce respiratory allergy with Th2-dominated response in mice. Toxicology 218, 39–47 (2006). 
46. Holgate, S. T. Innate and adaptive immune responses in asthma. Nat.Med. 18, 673–683 (2012). 
47. van Helden, M. J. & Lambrecht, B. N. Dendritic cells in asthma. Curr. Opin. Immunol. 25, 745–754 (2013). 
48. Kopf, M., Schneider, C. & Nobs, S. P. The development and function of lung-resident macrophages and dendritic cells. Nat. Immunol. 16, 36–44 (2015). 
49. Willart, M. a. M. & Lambrecht, B. N. The danger within: endogenous danger signals, atopy and asthma. Clin. Exp. Allergy J. Br. Soc. Allergy Clin. Immunol. 39, 12–19 (2009). 
50. Lambrecht, B. N., Salomon, B., Klatzmann, D. & Pauwels, R. A. Dendritic cells are required for the development of chronic eosinophilic airway inflammation in response to inhaled antigen in sensitized mice. J Immunol 160, 4090–4097 (1998). 
General discussion 
114  
51. Lambrecht, B. N. & Hammad, H. Taking our breath away: dendritic cells in the pathogenesis of asthma. Nat.Rev.Immunol. 3, 994–1003 (2003). 
52. Provoost, S., Maes, T., Joos, G. F. & Tournoy, K. G. Monocyte-derived dendritic cell recruitment and allergic T(H)2 responses after exposure to diesel particles are CCR2 dependent. JAllergy ClinImmunol 129, 483–491 (2012). 
53. Vanoirbeek, J. A., De Vooght, V., Nemery, B. & Hoet, P. H. Multiple challenges in a mouse model of chemical-induced asthma lead to tolerance: ventilatory and inflammatory responses are blunted, immunologic humoral responses are not. Toxicology 257, 144–152 (2009). 
54. Van den Broeck, W., Derore, A. & Simoens, P. Anatomy and nomenclature of murine lymph nodes: Descriptive study and nomenclatory standardization in BALB/cAnNCrl mice. J. Immunol. Methods 312, 12–19 (2006). 
55. Dearman, R. J., Basketter, D. A. & Kimber, I. Characterization of chemical allergens as a function of divergent cytokine secretion profiles induced in mice. Toxicol.Appl.Pharmacol. 138, 308–316 (1996). 
56. Malissen, B., Tamoutounour, S. & Henri, S. The origins and functions of dendritic cells and macrophages in the skin. Nat. Rev. Immunol. 14, 417–428 (2014).
  
 
 
 
 
 
 
 
 
 
Summary 
 

 Summary 
117  
Asthma is a heterogeneous airway disease, characterized by chronic airway inflammation, variable 
airway remodeling, reversible airway obstruction and non-specific airway hyperreactivity (AHR). The 
respiratory symptoms include wheezing, shortness of breath, chest tightness and cough. In adults, 9-
15% of all asthma cases are attributable to exposure to agents on the workplace, called occupational 
asthma (OA). OA is therefore one of the most common forms of occupational lung disease in many 
industrialized countries.  
Based on the presence or absence of an asymptomatic latency period, OA can be divided into two 
phenotypes. First, immunological OA appears after a latency period of exposure (months to years) 
necessary for acquiring immune sensitization to the causal agent. This phenotype of OA encompasses 
OA induced by an immunoglobulin (Ig)E mediated mechanism (most high- and some low- molecular 
weight agents), and OA in which the IgE mechanism has not been consistently demonstrated (low 
molecular weight agents such as western red cedar, acrylates and isocyanates). Second, non-
immunological OA, in which asthma occurs after an acute exposure to high concentrations of an irritant, 
without a latency period, termed irritant-induced asthma. 
Diisocyanates are reactive chemicals, used in the polyurethane industry for the manufacture of flexible 
and rigid foams, fibers, paints and varnishes. They are one of the most important causes of OA. Low 
airborne levels of diisocyanates, even below the established permissible exposure level, can trigger 
asthmatic reactions in individuals sensitized to diisocyanates. An important difference between protein-
induced allergic asthma and chemical-induced asthma, is that the chemicals first need to bind to 
endogenous proteins before they become recognizable by the immune system resulting in a different, 
not yet fully delineated mechanism of action.  
In this doctoral thesis, we used an established acute mouse model of chemical-induced asthma (chapter 
3). This model consists of a dermal sensitization phase followed by a single airway exposure. This acute 
exposure model results in AHR and airway inflammation that is mainly dominated by neutrophils in 
conjunction with the presence of eosinophils. This acute mouse model has been suitable to validate 
chemicals for their asthmatic potency and to study several key players in chemical-induced asthma. 
However, due to the short-term exposure time, there are some limitations in this model such as the 
absence of a robust lung inflammation and airway remodeling. Therefore, we developed a chronic 
(chapter 4) and a sub-chronic (chapter 5) mouse model of chemical-induced asthma. 
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1. Study of the cross-reactivity between MDI and TDI (chapter 3) 
In the first part of this thesis, we optimized the acute mouse model using 2,4-toluene diisocyanate in 
C57Bl/6 mice, and validated the sensitization and asthmogenic potency of 4,4-methylene diphenyl 
diisocyanate (MDI). Both TDI and MDI were potent sensitizers and asthmogens in the C57Bl/6 mice. 
However MDI was, compared to TDI, a somewhat weaker dermal sensitizer and asthmogen. 
Additionally, we investigated whether there is cross-reactivity between TDI and MDI. We studied the 
cross-reactivity between TDI and MDI by dermally sensitizing mice with TDI followed by an airway 
challenge with MDI and vice versa. In this acute model, with a single airway challenge, we did not 
observed cross-reactivity between TDI and MDI. 
2. Development of a chronic and sub-chronic mouse model and study the presence of dendritic cells  
2.1 Development of a chronic intranasal mouse model (chapter 4) 
In the second part of this thesis, we attempted to obtain a severe chemical-induced asthmatic 
phenotype with pronounced lung inflammation and airway remodeling. Chronic intranasal exposure 
(daily intranasal instillation exposure – 5 days a week - for five consecutive weeks) resulted in a 
predominant T helper (Th1) systemic immune response, without AHR nor recruitment of inflammatory 
and dendritic cells (DC). By adding prior dermal sensitization, intranasal exposures resulted in a 
predominant systemic Th2 immune response accompanied with AHR. Still, the AHR was not 
accompanied with airway inflammation nor recruitment of DC in the lung, mimicking the clinically 
relevant paucigranulocytic phenotype of asthma. As a conclusion, dermal contact with TDI prior to long-
term respiratory exposures determines the outcome of systemic immune sensitization and the presence 
of AHR.  
2.2 Development of a sub-chronic oropharyngeal mouse model (chapter 5) 
Since we were unable to find airway inflammation in the chronic intranasal mouse model, the last part 
of this thesis focused on the development of a mouse model using an oropharyngeal instillation 
technique to expose the lower airways to TDI. Multiple oropharyngeal TDI exposures resulted in airway 
inflammation accompanied with DC recruitment to the lung, which is indicative of the initiation of an 
adaptive immune response in the lung. However, the type of inflammation is shaped by the route of 
exposure. Without skin exposure the inflammation is dominated by mainly neutrophils, which is 
indicative for irritant-induced inflammation, while prior skin sensitization with TDI resulted in an 
eosinophilic airway inflammation accompanied with AHR, which is indicative for an immune-mediated 
inflammatory phenotype of asthma. As a conclusion, DC are recruited to the lungs in the presence of 
inflammation, and pre-dermal contact with TDI determines the type of lung inflammation (eosinophilic 
versus neutrophilic) and the presence of AHR.
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Astma is een heterogene luchtwegaandoening, gekenmerkt door chronisch luchtwegontsteking, 
luchtwegremodelering, reversibele luchtwegobstructie en niet-specifieke bronchiale hyperreactiviteit 
(BHR). De klinische symptomen zijn piepende ademhaling, kortademigheid, beklemmend gevoel aan de 
borststreek en hoesten. In de volwassen populatie wordt 9-10% van de astmagevallen toegeschreven 
aan beroepsmatige blootstellingen, ook wel beroepsastma (BA) genoemd. BA wordt eveneens aanzien 
als de meest voorkomende werk-gerelateerde longziekte. 
BA kan, door middel van de aan of afwezigheid van een asymptomatische latentieperiode, 
onderverdeeld worden in twee fenotypes. Het eerste fenotype, immunologisch gemedieerd BA 
genoemd, ontstaat na een latentieperiode van maanden tot jaren. Tijdens deze periode worden 
personen gesensibiliseerd aan het causaal agens. Dit fenotype van astma kan zowel geïnduceerd 
worden door immunoglobuline (Ig)E gemediëerde mechanismen (door hoog- en enkele laag 
molecuulgewicht agens) als door niet-IgE gemediëerde mechanismen (door laag molecuulgewicht 
agens zoals western red cedar, acrylaten en isocyanaten). Het tweede fenotype, niet-immunologisch 
gemedieerd BA genoemd, ontstaat na een korte hoge blootstelling aan een irriterende stof. Dit fenotype 
is niet gekenmerkt door een latentieperiode en wordt irritant geïnduceerd astma genoemd. 
Diisocyanaten zijn reactieve chemicaliën die gebruikt worden in de polyurethaan industrie voor de 
productie van polyurethaanschuim, verven, vernissen, en vormen een belangrijke oorzaak van BA. Eens 
een persoon gesensibiliseerd is, kunnen zeer lage diisocyanaat concentraties in de lucht, zelfs onder de 
wettelijk vastgelegde grenswaarden, een astma-aanval uitlokken. In tegenstelling tot hoog 
molecuulgewichten, worden chemicaliën met een laag moleculairgewicht pas herkenbaar door het 
immuunsysteem na binding met endogene proteïnen. Het immunologisch mechanisme waarmee 
chemicaliën met een laag moleculairgewicht astma veroorzaken is nog niet volledig gekend.  
In deze doctoraatsthesis hebben we een bestaand acuut muismodel van chemisch-geïnduceerd astma 
gebruikt (hoofdstuk 3). Dit model bestaat uit een dermale sensibilisatie fase gevolgd door één enkele 
luchtwegblootstelling die resulteert in immuun sensibilisatie, BHR en luchtweginflammatie. Deze laatste 
bestaat voornamelijk uit neutrofielen en beperkt ook uit eosinofielen. Aan de hand van dit acuut model 
zijn al verschillende chemicaliën gevalideerd voor hun astmatische potentie. Hiernaast is het acuut 
model ook gebruikt om het onderliggend mechanismen van chemisch-geinduceerd BA te onderzoeken. 
Het nadeel van dit acuut model is dat robuuste longontsteking en luchtwegremodelering afwezig zijn, 
wat ook belangrijke kenmerken van astma zijn. Om ook deze kenmerken van astma te kunnen 
onderzoeken hebben we een chronisch (hoofdstuk 4) en een sub-chronisch (hoofdstuk 5) muismodel 
van chemisch-geïnduceerd astma ontwikkeld. 
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1. Studie van de kruisreactiviteit tussen MDI en TDI (hoofdstuk 3) 
In het eerste gedeelte van deze thesis hebben we het acuut model geoptimaliseerd in de C57Bl/6 
muizenstam gebruikmakend van de model agens 2,4-tolueendiisocyanaat (TDI). Vervolgens hebben we 
de sensibiliserende en astmatische potentie van 4,4’-methyleendifenyldiisocyanaat (MDI) gevalideerd. 
De resultaten toonden aan dat zowel TDI als MDI potente astmogenen zijn, maar MDI is een zwakkere 
dermale sensibilisator en astmogeen dan TDI. Tevens hebben we de kruisreactiviteit tussen TDI en MDI 
onderzocht. Hiervoor zijn de muizen dermaal gesensibiliseerd met TDI gevolgd door een 
luchtwegblootstelling aan MDI en omgekeerd. In dit acuut model, met één enkele 
luchtwegblootstelling, vonden we geen kruisreactiviteit tussen TDI en MDI. 
2. Ontwikkeling van een chronisch en sub-chronisch muismodel en het bestuderen van de aanwezigheid van dendritische cellen  
2.1 Ontwikkeling van een chronisch intranasaal muismodel (hoofdstuk 4) 
In het tweede gedeelte van deze thesis hebben we geprobeerd om een fenotype van ernstig chemisch-
geïnduceerd astma te ontwikkelen die gekarakteriseerd is door een uitgesproken luchtweginflammatie 
en luchtwegremodelering. Dagelijkse intranasale blootstellingen aan TDI (5 dagen per week voor 5 
opeenvolgende weken) resulteerden in een sterke systemische T helper (Th)1 immuunrespons zonder 
BHR, zonder longinflammatie en afwezigheid van dendritische cellen (DC) in de long. Indien de muizen 
eerst dermaal werden gesensibiliseerd met TDI, resulteert deze dagelijkse intranasale blootstelling in 
een sterke systemische Th2 immuunrespons en BHR, maar nog altijd zonder longinflammatie en DC in 
de long. Dit muismodel bootst het klinisch relevant ‘paucigranulocytair’ fenotype van chemisch-
geïnduceerd astma na. Gebruikmakend van dit model voor TDI-gemediëerde pulmonaire reacties 
kunnen we concluderen dat voorgaand dermaal contact met TDI de immunologische respons beïnvloed 
en de aanwezigheid van BHR bepaalt na een chronische luchtwegblootstelling aan lage concentraties 
TDI. 
2.2 Ontwikkeling van een sub-chronisch orofaryngeaal muismodel (hoofdstuk 5) 
Aangezien dat luchtweginflammatie niet aanwezig was in het chronisch intranasaal model, werd in het 
laatste gedeelte van deze thesis gefocust op het ontwikkelen van een muismodel waarin we een andere 
methode voor luchtwegblootstelling gebruiken, namelijk de orofaryngeale instillatie techniek. Aan de 
hand van deze instillatie kunnen we de lagere luchtwegen blootstellen. Meerdere orofaryngeale 
bloostellingen aan TDI resulteerden in een migratie van inflammatoire cellen en DC naar de long, deze 
laatste wijst op de initiatie van een adaptief immuunsysteem. Indien de muizen eerst dermaal werden 
gesensibiliseerd met TDI resulteerden de orofaryngeale TDI instillaties in luchtwegontsteking, die 
voornamelijk gekenmerkt was door eosinofielen en BHR. Deze longrespons wijst op een immuun-
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gemedieerd inflammatoir fenotype van astma. In afwezigheid van deze dermale sensibilisatie 
resulteerden de orofaryngeale instillaties in een luchtwegontsteking die voornamelijk gekenmerkt werd 
door de aanwezigheid van neutrofielen, zonder BHR. Deze luchtweg respons wijst op irritant-
geïnduceerde inflammatie. Uit deze resultaten kunnen we concluderen dat DC naar de long migreren 
in aanwezigheid van inflammatoire cellen. Eveneens kunnen we concluderen dat voorgaande dermale 
sensibilisatie het type van luchtwegontsteking (eosinofielen of neutrofielen) en de aanwezigheid van 
BHR bepaalt.  
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